



Airdoc 鷹瞳

Beijing Airdoc Technology Co., Ltd.

北京鷹瞳科技發展股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(於中華人民共和國註冊成立的股份有限公司)

Stock Code 股份代號: 2251

Interim Report 2023
中期報告

CONTENTS

目 錄

Corporate Information	2	公司資料
Financial Summary	5	財務概要
Management Discussion and Analysis	6	管理層討論與分析
Other Information	33	其他資料
Independent Review Report	54	獨立審閱報告
Interim Condensed Consolidated Statement of Profit or Loss	56	中期簡明綜合損益表
Interim Condensed Consolidated Statement of Comprehensive Income	57	中期簡明綜合收益表
Interim Condensed Consolidated Statement of Financial Position	58	中期簡明綜合財務狀況表
Interim Condensed Consolidated Statement of Changes in Equity	60	中期簡明綜合權益變動表
Interim Condensed Consolidated Statement of Cash Flows	61	中期簡明綜合現金流量表
Notes to Interim Condensed Consolidated Financial Information	64	中期簡明綜合財務資料附註
Definitions and Glossary of Technical Terms	94	釋義及技術性詞彙表

CORPORATE INFORMATION

公司資料

BOARD OF DIRECTORS

Executive Directors

Mr. ZHANG Dalei (張大磊)
(Chairman and chief executive officer)
 Mr. GAO Fei (高斐) *(ceased on January 13, 2023)*
 Dr. CHEN Yuzhong (陳羽中)
 Mr. CHEN Hailong (陳海龍)
 Ms. WANG Lin (王林) *(effective from March 30, 2023)*

Non-executive Directors

Ms. WANG Mi (王謐) *(ceased on January 13, 2023)*
 Mr. CHEN Xin (陳欣) *(effective from May 19, 2023)*
 Ms. ZHU Tingyao (朱艇遙) *(effective from March 30, 2023 and ceased on July 27, 2023)*

Independent Non-executive Directors

Mr. NG Kong Ping Albert (吳港平)
 Dr. WU Yangfeng (武陽豐)
 Dr. HUANG Yanlin (黃彥林)

SUPERVISORS

Mr. WEI Yubo (魏宇博)
 Ms. BAI Huihui (白惠惠)
 Dr. LUO Ting (羅婷)

AUDIT COMMITTEE

Mr. NG Kong Ping Albert (吳港平) *(Chairman)*
 Dr. HUANG Yanlin (黃彥林)
 Dr. WU Yangfeng (武陽豐)

REMUNERATION AND APPRAISAL COMMITTEE

Dr. HUANG Yanlin (黃彥林) *(Chairman)*
 Mr. GAO Fei (高斐) *(ceased on January 13, 2023)*
 Mr. NG Kong Ping Albert (吳港平)
 Ms. WANG Lin (王林) *(effective from March 30, 2023)*

NOMINATION COMMITTEE

Mr. ZHANG Dalei (張大磊) *(Chairman)*
 Dr. HUANG Yanlin (黃彥林)
 Dr. WU Yangfeng (武陽豐)

董事會

執行董事

張大磊先生
(主席兼首席執行官)
 高斐先生 *(於2023年1月13日卸任)*
 陳羽中博士
 陳海龍先生
 王林女士 *(於2023年3月30日生效)*

非執行董事

王謐女士 *(於2023年1月13日卸任)*
 陳欣先生 *(於2023年5月19日生效)*
 朱艇遙女士 *(於2023年3月30日生效並於2023年7月27日卸任)*

獨立非執行董事

吳港平先生
 武陽豐博士
 黃彥林博士

監事

魏宇博先生
 白惠惠女士
 羅婷博士

審核委員會

吳港平先生 *(主席)*
 黃彥林博士
 武陽豐博士

薪酬與考核委員會

黃彥林博士 *(主席)*
 高斐先生 *(於2023年1月13日卸任)*
 吳港平先生
 王林女士 *(於2023年3月30日生效)*

提名委員會

張大磊先生 *(主席)*
 黃彥林博士
 武陽豐博士

CORPORATE INFORMATION

公司資料

STRATEGY COMMITTEE

Mr. ZHANG Dalei (張大磊) (*Chairman*)
Mr. NG Kong Ping Albert (吳港平)
Dr. WU Yangfeng (武陽豐)

AUTHORIZED REPRESENTATIVES

Mr. ZHANG Dalei (張大磊)
Ms. SO Lai Shan (蘇麗珊)

JOINT COMPANY SECRETARIES

Ms. YANG Wenting (楊文婷)
Ms. SO Lai Shan (蘇麗珊)
(*ACG (CS, CGP) HKACG (CS, CGP)*)

HEAD OFFICE, REGISTERED OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

Room 21, 4th Floor, Building 2, A2 Yard
West Third Ring North Road
Haidian District
Beijing
PRC

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1901, 19/F, Lee Garden One
33 Hysan Avenue
Causeway Bay
Hong Kong

H SHARE REGISTRAR

Tricor Investor Services Limited
17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

戰略委員會

張大磊先生(主席)
吳港平先生
武陽豐博士

授權代表

張大磊先生
蘇麗珊女士

聯席公司秘書

楊文婷女士
蘇麗珊女士(特許公司治理公會會士、
香港公司治理公會會士)

中國的總部、註冊辦事處和 主要營業地點

中國
北京市
海淀區
西三環北路
甲2號院2號樓4層21室

香港主要營業地點

香港
銅鑼灣
希慎道33號
利園一期19樓1901室

H股證券登記處

卓佳證券登記有限公司
香港
夏慤道16號
遠東金融中心17樓

CORPORATE INFORMATION

公司資料

HONG KONG LEGAL ADVISER

Kirkland & Ellis
26/F, Gloucester Tower
The Landmark
15 Queen's Road Central
Hong Kong

PRC LEGAL ADVISER

Zhong Lun Law Firm
22-31/F, South Tower of CP Center
20 Jin He East Avenue
Chaoyang District
Beijing
PRC

AUDITOR

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

STOCK CODE

2251

COMPANY WEBSITE

www.airdoc.com

香港法律顧問

凱易律師事務所
香港
皇后大道中15號
置地廣場
告羅士打大廈26樓

中國法律顧問

中倫律師事務所
中國
北京市
朝陽區
金和東路20號院
正大中心南塔22-31層

核數師

安永會計師事務所
執業會計師
註冊公共利益實體核數師
香港
鰂魚涌
英皇道979號
太古坊一座27樓

股份代號

2251

公司網站

www.airdoc.com

FINANCIAL SUMMARY

財務概要

A summary of the results and of the assets and liabilities of the Group for the Reporting Period together with the comparative figures for the corresponding previous period is set out as follows:

本集團於報告期內的業績以及資產及負債概要，連同對應上期的比較數字載列如下：

		Six months ended June 30, 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue	收入	82,502	37,407
Cost of sales	銷售成本	(31,138)	(15,336)
Gross profit	毛利	51,364	22,071
Loss before tax	除稅前虧損	(40,529)	(99,684)
Loss for the period	期內虧損	(41,017)	(99,684)
Loss per share	每股虧損		
Basic and diluted (RMB)	基本及攤薄(人民幣元)	(0.36)	(0.98)
		As of June 30, 2023 截至2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	As of December 31, 2022 截至2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Financial Position	財務狀況		
Non-current assets	非流動資產	364,668	64,137
Current assets	流動資產	1,408,821	1,675,818
Non-current liabilities	非流動負債	18,178	3,928
Current liabilities	流動負債	90,262	64,665
Net assets	資產淨值	1,665,049	1,671,362
Total equity attributable to equity shareholders of the Company	本公司權益股東應佔權益總額	1,639,178	1,666,125
Non-controlling interests	非控股權益	25,871	5,237

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

BUSINESS OVERVIEW

We are an AI-based medical device company with an advanced platform of AI-empowered retina-based deep learning algorithms. We are one of the first to provide AI-empowered retina-based early detection, diagnosis and health risk assessment solutions in China. With the feature of integrated software and hardware solutions, we provide our AI-based SaMDs, health risk assessment solutions and hardware devices to a wide range of healthcare environments, enabling us to commercialize and sell not only to clinical departments in hospitals, but also to other types of medical institutions, various consumer healthcare environments and eye health management settings.

In the first half of 2023, upholding the mission of “Accessible and Affordable to Everyone”, we had been committed to diligently advancing our business expansion. With our continued efforts to boost sales, our revenue increased by 120.6% from RMB37.4 million for the six months ended June 30, 2022 to RMB82.5 million for the six months ended June 30, 2023. This growth was driven by the improved performance of our three main business pillars, namely, Airdoc Medical (鷹瞳醫療), Airdoc Health (鷹瞳健康) and Airdoc Eye Health (鷹瞳眼健康). For the period ended June 30, 2023, each of our business pillars saw a year-over-year revenue growth: (i) revenue from Airdoc Medical increased by 137.3% from RMB12.6 million to RMB29.8 million, (ii) revenue from Airdoc Health increased by 26.0% from RMB17.2 million to RMB21.7 million, and (iii) revenue from Airdoc Eye Health increased by 307% from RMB7.6 million to RMB31.0 million, which is primarily attributable to the continual expansion of our main business into hospital and primary healthcare institutions, as well as our persistent efforts in promoting integration of diagnosis and treatment and strategically extending our products and services to post-diagnostic treatment and care. In the first six months of 2023, we had detected 2.96 million cases (“Uses”) via our SaMDs and health risk assessment solutions, representing a year-over-year increase of 81.2%.

業務概覽

我們是一家人工智能醫療器械公司，擁有先進的人工智能視網膜影像識別深度學習算法平台。我們是中國首批通過人工智能視網膜影像識別技術提供早期檢測、診斷及健康風險評估解決方案的公司之一。通過軟硬件一體化的解決方案，我們向各類大健康服務場景提供人工智能SaMD、健康風險評估解決方案和硬件設備，從而使我們產品的商業化不僅覆蓋醫院臨床科室，同時可以向其他類型的醫療機構、各類大健康場景及眼健康管理場景進行銷售。

於2023年上半年，我們秉承「讓健康無處不在」的使命，一直致力於努力推進業務拓展。隨著我們持續努力促進銷售，我們的收入自截至2022年6月30日止六個月的人民幣37.4百萬元增加120.6%至截至2023年6月30日止六個月的人民幣82.5百萬元。該增長得益於我們三大支柱業務，即鷹瞳醫療、鷹瞳健康及鷹瞳眼健康的業績進步。截至2023年6月30日止期間，我們各支柱業務的收入均實現同比增長：(i)鷹瞳醫療的收入自人民幣12.6百萬元增加137.3%至人民幣29.8百萬元；(ii)鷹瞳健康的收入自人民幣17.2百萬元增加26.0%至人民幣21.7百萬元；及(iii)鷹瞳眼健康的收入自人民幣7.6百萬元增加307%至人民幣31.0百萬元，主要由於本集團的主要業務不斷擴展至醫院及基層醫療機構，以及我們堅持不懈地推進診療一體化，並將我們的產品及服務戰略性地延伸至檢後服務。於2023年首六個月，我們通過SaMD及健康風險評估解決方案檢出2.96百萬病例（「檢測次數」），同比增長81.2%。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our newly-established production factory in Changsha had commenced operations, achieving in-house hardware production, economies of scale and effective cost control. Through the continual investment in research and development, our gross profit margin increased from 59.0% for the six months ended June 30, 2022 to 62.3% for the six months ended June 30, 2023. As a result of the aforesaid endeavors, our loss significantly narrowed from RMB99.7 million for the six months ended June 30, 2022 to RMB41.0 million for the six months ended June 30, 2023.

Our AI-FUNDUSCAMERA-P and myopia treatment product won the “Special Commendation Golden Awards” at the Salon International des Inventions de Genève in April 2023. Such global recognition validates our products’ wide acceptance among invention professionals worldwide. Our products have received recognition from several renowned medical journals, such as The Lancet, which showed that (i) our AI detection system for retinal images is able to identify 14 types of abnormalities, and (ii) our AI algorithm is able to achieve a high AUC between 0.95 and 0.98 for these abnormalities. Science Bulletin, another renowned medical journal, showed that AI algorithm is able to identify the risk of ICVD non-invasively, quickly and conveniently, achieving AUC of 0.97. Experts of Beijing Tongren Hospital suggested that fundus detection should be vastly used as a basic tool for pre-scanning the health condition of all citizens. Additionally, our fundus camera and automated method for fundus imaging was honored with the Excellence Award at the 24th China Patent Awards. Our fundus camera generates different types of reports tailored to our users’ needs, with the premium version capable of pre-screening up to nearly 50 types of disease risks and lesions.

我們於長沙的新建生產工廠已開始營運，實現內部硬件生產、規模經濟及完善成本控制。通過持續投入研發，我們將毛利率由截至2022年6月30日止六個月的59.0%提高至截至2023年6月30日止六個月的62.3%。由於上述努力，我們的虧損由截至2022年6月30日止六個月的人民幣99.7百萬元大幅減少至截至2023年6月30日止六個月的人民幣41.0百萬元。

我們的AI-FUNDUSCAMERA-P及近視治療產品於2023年4月在日內瓦國際發明展上榮獲「特別表彰金獎」。此全球認可證明了我們的產品於全球發明專業人士中的廣泛認可。我們的產品已獲得《柳葉刀》等著名醫學雜誌的認可。該雜誌表明：(i) 我們的視網膜影像人工智能檢測系統能夠識別14種異常，及(ii)我們的人工智能算法識別該等異常的AUC高達0.95至0.98。另一份著名醫學期刊《Science Bulletin》則顯示，使用我們的人工智能算法能夠無創、快速且便捷地識別缺血性心血管疾病(ICVD)風險，AUC為0.97。北京同仁醫院專家建議，應廣泛使用眼底檢測作為預掃描全民健康狀況的一種基本工具。此外，我們的眼底相機及自動化眼底成像方法於第24屆中國專利獎中榮獲優秀獎。我們的眼底相機可根據用戶需求生成不同類型的報告，高級版可預掃描出近50種疾病風險及病灶。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

We plan to launch, in order of the detection rate, our in-house developed treatment and control solutions that are compatible with external treatment plans, so as to achieve the integration of diagnosis and treatment, which marks the next chapter in our business development. In response to this, we have taken the initial step. We have launched a myopia treatment device, specifically designed for tessellated fundus, a condition for which our product has achieved the highest positive detection rate amongst its covered diseases. This product won the highest award in the Geneva International Invention Patent. During the Reporting Period, we empowered the traditional treatments for strabismus and amblyopia by using our AI technologies and developed a strabismus and amblyopia treatment product that are increasingly recognized by professional doctors and customers. Furthermore, the business of Airdoc Eye Health is facing strengthened regulatory supervision this year that may lead to a decrease in the number of competitors in a market with tremendous unmet demand, which, in the long run, will be a potential benefit to a company like ours that has more advanced R&D capabilities than the peers.

我們計劃按照檢出率的順序，推出我們與外部治療計劃相結合的內部開發治療及干預解決方案，以實現診斷及治療一體化，此舉標誌著我們業務發展的新篇章。對此我們已經邁出了第一步，針對我們產品覆蓋病灶中陽性檢出率排名第一的豹紋狀眼底，推出了一款近視治療儀產品。該產品榮獲日內瓦國際發明專利最高獎。於報告期內，我們利用人工智能技術賦能斜視及弱視的傳統治療方法，開發了斜視及弱視治療產品，受到專業醫生及客戶的日益認可。此外，鷹瞳眼健康業務今年面臨著更為嚴格的監督監管，這可能會導致於剛需尚未得到滿足的廣闊市場中競爭對手數量減少，從長遠來看，對於像我們這樣擁有比同行更為先進的研發能力的公司而言，這將是一個潛在優勢。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our Portfolio

To address the largely unmet medical needs of early detection and diagnosis of chronic diseases, we developed our AI-empowered retina-based early detection, diagnosis and health risk assessment solutions potentially capable of covering a wide range of diseases and lesions. Our portfolio includes SaMDs for detection and diagnosis, health risk assessment solutions and hardware devices, forming an integrated solution of AI-based software and hardware. The following diagram sets forth key details of our portfolio as of the date of this report:

我們的產品組合

為解決慢性疾病早期檢測及診斷的巨大醫療需求缺口，我們開發了人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案，有望涵蓋廣泛的疾病及病灶。我們的產品組合包括用於檢測及診斷的SaMD、健康風險評估解決方案及硬件設備，形成一個基於人工智能的軟件及硬件一體化的解決方案。下圖載列截至本報告日期我們產品組合的主要詳情：



Product Type 產品類型	Product 產品	Indication 適應症	Class Of Medical Device 醫療器械類型	R&D Stage 研發階段		Registration Stage 註冊階段		Expected timeline for the next milestone 下一個里程碑的預期時間表	Expected NMPA Registration Certificate Application 預期向國家藥監局提交註冊證書申請	
				Early Stage Development ¹ 開發初期 ¹	Late Stage Development ² 開發後期 ²	Registrational Trial 註冊實驗	NMPA Submission 向國家藥監局提交申請			NMPA Approval 國家藥監局批准
SaMDs for Detection and Diagnosis 用於檢測和診斷的SaMD	Airdoc-AIFUNDUS	Ver. 1.0 1.0 版本	Diabetic retinopathy 糖尿病視網膜病變	Class III 第三類					Approved in August 2020 2020年8月獲批	
		Ver. 2.0 2.0 版本	Hypertensive retinopathy 高血壓性視網膜病變	Class III 第三類					Applied in Q4 2022 2022年第四季度申請	
			Retinal vein occlusion 視網膜靜脈阻塞	Class III 第三類						
		Age-related macular degeneration (AMD) 年齡相關性黃斑變性	Class III 第三類							
	Ver. 3.0 3.0 版本	Pathological myopia 病理性近視	Class III 第三類							
		Retinal detachment 視網膜脫落	Class III 第三類				Q2 2025 2025年第二季度		To apply in H1 2026 2026年上半年申請	
	Individual Products 獨立產品		Glaucoma detection 青光眼檢測	Class II 第二類						Approved in June 2020 2020年6月獲批
			Cataracts detection 白內障檢測	Class II 第二類						Approved in January 2022 2022年1月獲批
			ICVD / ASCVD	Class III 第三類				Q4 2025 2025年第四季度		To apply in H2 2026 2026年下半年申請
			Gestational diabetic retinopathy 妊娠期糖尿病視網膜病變	Class III 第三類				Q1 2025 2025年第一季度		To apply in H1 2026 2026年上半年申請
		Gestational hypertensive retinopathy 妊娠期高血壓性視網膜病變	Class III 第三類				Q1 2025 2025年第一季度		To apply in H1 2026 2026年上半年申請	
		Papilloedema intracranial hypertension retinopathy 顱內高壓相關視乳頭水腫視網膜病變	Class III 第三類				Q4 2025 2025年第四季度		To apply in H2 2026 2026年下半年申請	
	Anemia 貧血症	Class II 第二類				Q4 2024 2024年第四季度		To apply in Q4 2025 2025年第四季度申請		
Product Type 產品類型	Indication 適應症	R&D Stage 研發階段		Commercialization Stage 商業化階段						
		Early Stage Development ¹ 開發初期 ¹	Late Stage Development ² 開發後期 ²	Commercialization 商業化						
Health Risk Assessment Solutions ³ 健康風險評估方案 ³	55 types of lesions and diseases ⁴ 55種病灶和疾病 ⁴									
	Hyperthyroidism 甲狀腺機能亢進									
	Graves ophthalmopathy (external eye) 格雷夫斯眼病（外眼）									
	Retinal vein occlusion (prediction) 視網膜靜脈阻塞（預測）									
	Dementia 痴呆症									
	Parkinson's disease 帕金森病									
	Atrial fibrillation 房顫									
	Arteriosclerosis (middle or large artery) 動脈硬化（中動脈或大動脈）									
Product Type 產品類型	Product 產品	Class Of Medical Device 醫療器械類型	R&D Stage 研發階段		Registration Stage 註冊階段		Expected timeline for the next milestone 下一個里程碑的預期時間表	Expected NMPA Registration Certificate Application 預期向國家藥監局提交註冊證書申請		
			Early Stage Development ¹ 開發初期 ¹	Late Stage Development- Pilot Production ² 開發後期-試點生產 ²	NMPA Submission 向國家藥監局提交申請	NMPA Approval 國家藥監局批准				
Proprietary Hardware Device 自研硬件設備	AI-FUNDUSCAMERA-P	Class II 第二類						Approved in March 2021 2021年3月獲批		
	AI-FUNDUSCAMERA-D	Class II 第二類						Approved in July 2022 2022年7月獲批		
	AI-FUNDUSCAMERA-M	Class II 第二類				Q4 2023 2023年第四季度		To apply in Q4 2023 2023年第四季度申請		
	Myopia treatment product ⁵ 近視治療產品 ⁵	Class III 第三類				Q2 2024 2024年第二季度		Q4 2024 2024年第四季度		

Our Core Product
我們的核心產品

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

- | | |
|--|--|
| <p>1. Denotes the process of data collection, data labelling and model training.</p> | <p>1. 開發初期指數據收集、數據標記及模型訓練過程。</p> |
| <p>2. Denotes the process of data supplementation, algorithm training iteration and algorithm validation.</p> | <p>2. 開發後期指數據補充、算法訓練迭代及算法驗證過程。</p> |
| <p>3. No regulatory approval or registration is required for the sales of our health risk assessment solutions in consumer healthcare environments and eye health management settings.</p> | <p>3. 在大健康和眼健康場景中，銷售我們的健康風險評估解決方案無需獲得監管批准或注冊。</p> |
| <p>4. During the Reporting Period, we offer health risk assessment solutions with the ability to detect risk indicators, including risk assessments of retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease and anemia.</p> | <p>4. 於往績記錄期間，我們提供具有檢測健康風險指標能力的健康風險評估解決方案，包括對視網膜異常、視網膜血管異常、玻璃體異常、視網膜腫瘤、視神經病變、黃斑病變、先天性視網膜異常、心血管異常及貧血症進行的風險評估。</p> |
| <p>5. Denotes the process of product planning, product definition, engineering verification and design verification.</p> | <p>5. 開發初期指產品規劃、產品定義、工程驗證及設計驗證過程。</p> |
| <p>6. Denotes the process of production verification.</p> | <p>6. 試點生產指生產驗證過程。</p> |
| <p>7. The first generation of our myopia treatment product has obtained a Class II medical device registration certificate and has entered the commercialization stage.</p> | <p>7. 我們的第一代近視治療產品已取得第二類醫療器械註冊證書，並已進入商業化階段。</p> |

SaMDs for Detection and Diagnosis

We have Airdoc-AIFUNDUS, our in-house developed Core Product, and a pipeline of seven other in-house developed individual SaMDs in our SaMD portfolio.

用於檢測及診斷的SaMD

我們的SaMD產品組合中包含Airdoc-AIFUNDUS，即我們自主研發的核心產品，以及七款其他自主研發的獨立SaMD。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Airdoc-AIFUNDUS – Our Core Product

Our Airdoc-AIFUNDUS is an AI-based SaMD that uses sophisticated deep learning algorithms to accurately detect and diagnose chronic diseases from retinal images. We developed Airdoc-AIFUNDUS based on our proprietary AI-empowered retina-based early detection, diagnosis and health risk assessment technology platform, which is driven by deep learning technologies and fully validated in terms of scientific theory, clinical trial data and clinical pathway.

We have three versions of Airdoc-AIFUNDUS. Our Airdoc-AIFUNDUS (1.0) was the first AI-empowered retina-based auxiliary diagnosis product that obtained the Class III medical device registration certificate from the NMPA for assisting physicians in medical institutions with detecting and diagnosing diabetic retinopathy. In our multi-center clinical trial with 1,000 enrolled patients, our Airdoc-AIFUNDUS (1.0) demonstrated an industry-leading sensitivity of 91.75% and specificity of 93.10%. Moreover, our Airdoc-AIFUNDUS (1.0) is widely compatible with most fundus cameras on the market, which enables us to be well-positioned to capture the significant market opportunity. With diabetic retinopathy being one of the most common diabetes complication, we have marketed our Airdoc-AIFUNDUS (1.0) to the departments of endocrinology, ophthalmology and physical examination in hospitals.

Airdoc-AIFUNDUS – 我們的核心產品

我們的Airdoc-AIFUNDUS為一款人工智能SaMD，它使用複雜的深度學習算法通過視網膜影像準確地檢測及診斷慢性疾病。利用我們獨有的基於人工智能視網膜影像識別的早期檢測、診斷及健康風險評估技術平台，我們開發了Airdoc-AIFUNDUS，該產品由深度學習技術驅動並在科學理論、臨床試驗數據及臨床路徑方面都得到了充分驗證。

我們擁有三個版本的Airdoc-AIFUNDUS。我們的Airdoc-AIFUNDUS (1.0)是首個獲得國家藥監局第三類醫療器械註冊證書的人工智能視網膜影像識別輔助診斷產品，協助醫療機構的醫生檢測及診斷糖尿病視網膜病變。在我們招募1,000名患者的多中心臨床試驗中，我們的Airdoc-AIFUNDUS (1.0)顯示出行業領先的91.75%的靈敏度及93.10%的特異度。此外，我們的Airdoc-AIFUNDUS (1.0)可廣泛兼容市面上的大多數眼底相機，從而使我們可以更好地抓住重要的市場機會。糖尿病視網膜病變為最常見的糖尿病併發症之一，我們向醫院的內分泌科、眼科及體檢科室推銷Airdoc-AIFUNDUS (1.0)。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Airdoc-AIFUNDUS (2.0) is designed for the auxiliary diagnosis of hypertensive retinopathy, retinal vein occlusion and AMD. Upon completion of the entire process of clinical trial in the third quarter of 2022, we have applied to the NMPA for registration approval for the new indications in the fourth quarter of 2022. Our Airdoc-AIFUNDUS (2.0) has the potential to become the first AI-based auxiliary diagnosis SaMD in China that is expended with multiple indications approved. After obtaining the registration approval of new indications, we plan to market our Airdoc-AIFUNDUS (2.0) to the departments of cardiology and neurology in addition to the departments in hospitals mentioned above and promote it to patients with high blood pressure or at high risk of retinal vein occlusion.

Airdoc-AIFUNDUS (3.0) is designed for the auxiliary diagnosis of pathological myopia and retinal detachment to address the increasing myopia and vision problems in China, especially in younger generations.

Glaucoma Detection SaMD

Our glaucoma detection SaMD is used to process and analyze fundus images to detect glaucoma by measuring the Cup-to-Disc Ratio (“**CDR**”) of the optic disc. Featuring high accuracy, objectivity and efficiency, our glaucoma detection SaMD allows an editable and traceable analysis process while enabling physicians to rely less on experience and training to generate the CDR in early detection of glaucoma. We received a Class II medical device registration certificate for our glaucoma detection SaMD from the Shanghai branch of the NMPA in June 2020.

Airdoc-AIFUNDUS (2.0)旨在輔助診斷高血壓性視網膜病變、視網膜靜脈阻塞及年齡相關性黃斑變性(AMD)。我們已於2022年第三季度完成臨床試驗的全部流程，於2022年第四季度向國家藥監局已經申請新適應症的註冊批准。我們的Airdoc-AIFUNDUS (2.0)將有望成為中國首個增加多種獲批適應症的人工智能輔助診斷SaMD。獲得新適應症註冊批准後，除上述醫院科室外，我們還計劃向心臟科及神經科科室推銷我們的Airdoc-AIFUNDUS (2.0)，向患有高血壓或視網膜靜脈阻塞高風險患者推廣銷售該產品。

Airdoc-AIFUNDUS (3.0)旨在輔助診斷病理性近視及視網膜脫落，以解決中國日益增多的近視及視力問題，尤其是在年輕群體中的這些問題。

青光眼檢測SaMD

我們的青光眼檢測SaMD用於處理及分析眼底影像，從而通過測量視盤的杯盤比(「**CDR**」)來檢測青光眼。我們的青光眼檢測SaMD擁有高準確性、客觀性和高效率的特點，分析過程可編輯可追溯，同時可以讓醫生在青光眼的早期診斷中較少依賴經驗和培訓來生成CDR。我們於2020年6月就青光眼檢測SaMD取得上海市藥監局的第二類醫療器械註冊證書。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Cataracts Detection SaMD

Our cataracts detection SaMD is designed to detect cataracts by measuring the color value of the eye lens. Our cataracts detection SaMD can help ophthalmologists conveniently detect cataracts in a more standardized and scalable way and facilitate the process of grading cataracts in an accurate and objective fashion. We received a Class II medical device registration certificate for our cataracts detection SaMD from the Shanghai branch of the NMPA in January 2022.

Other SaMDs for Detection and Diagnosis

We are developing five other SaMDs designed for the detection and auxiliary diagnosis, covering ICVD and ASCVD, gestational diabetic retinopathy, gestational hypertensive retinopathy, papilledema intracranial hypertension retinopathy and anemia based on our AI-empowered retina-based early detection, diagnosis and health risk assessment technology platform.

白內障檢測SaMD

我們的白內障檢測SaMD旨在通過測量眼睛晶狀體的色值來檢測白內障。我們的白內障檢測SaMD可以幫助眼科醫生以更加標準化和可擴展的方式方便地檢測白內障，並以準確客觀的方式讓白內障分級的過程更方便。我們於2022年1月就白內障檢測SaMD取得上海市藥監局的第二類醫療器械註冊證書。

其他用於檢測及診斷的SaMD

基於人工智能視網膜影像識別早期檢測、輔助診斷及健康風險評估技術平台，我們正在開發其他五款SaMD旨在用於檢測及輔助診斷ICVD及ASCVD、妊娠期糖尿病視網膜病變、妊娠期高血壓性視網膜病變、顱內高壓相關視乳頭水腫視網膜病變及貧血症。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Health Risk Assessment Solutions

As chronic disease prevalence in China continues to rise, people's health awareness as well as the need for health risk assessment is also rapidly growing. To capture this massive market opportunity, we develop our AI-empowered retina-based health risk assessment solutions that provide end users with basic health assessment and detect risk indicators, including retinal abnormalities, retinal vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular diseases and anemia. Targeting a wide range of business settings that act as entry points of daily health monitoring and eye health management, we customize our health risk assessment solutions to cater to their unique needs raised in different healthcare environments. With our health risk assessment solutions currently covering 55 types of lesions and disease risks, we market it to various types of healthcare providers, which primarily include health checkup centers, insurance companies, optometry centers and pharmacies. We also plan to expand the coverage of diseases and lesions of our health risk assessment solutions to include hyperthyroidism, graves ophthalmopathy, retinal vein occlusion, dementia, Parkinson's disease, atrial fibrillation and arteriosclerosis, among others.

健康風險評估解決方案

隨著國內慢性疾病發病率持續攀升，人們的健康意識以及對健康風險評估的需求都在迅速提高。為了抓住這個巨大的市場機會，我們開發了基於人工智能視網膜影像識別技術的健康風險評估解決方案，向終端用戶提供基本的健康評估並檢測風險指標，包括視網膜異常、視網膜血管異常、玻璃體異常、視網膜腫瘤、視神經病變、黃斑病變、先天性視網膜異常、心腦血管異常及貧血症。針對各類承擔起日常健康管理和眼健康管理入口角色的商業場景，我們提供定製化的健康風險解決方案，以滿足不同醫療健康場景下的獨特需求。我們現有的健康風險評估解決方案覆蓋55種病灶和疾病風險，銷售給各類醫療健康供應商，主要包括體檢中心、保險公司、視光中心及藥房。我們還計劃擴大健康風險評估解決方案的疾病及病灶覆蓋範圍，增加甲狀腺機能亢進、格雷夫斯眼病、視網膜靜脈阻塞、癡呆症、帕金森氏症、房顫及動脈硬化等相關風險。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Proprietary Hardware Devices

We have three in-house developed fundus cameras that are compatible with our auxiliary diagnosis SaMDs and health risk assessment solutions, enabling us to provide integrated healthcare solutions that combine hardware and software. Together with our software products, our hardware devices are powered by on-device AI technologies such as speech recognition, speech synthesis and computer vision and can successfully address pain points of existing fundus cameras on the market at a fraction of the cost. In addition, we also launched a myopia control device loaded with our AI algorithm for dynamic real-time tracking. The device irradiates the fundus with repeated low-intensity light, increases the thickness of the choroid, and inhibits the excessive growth of the eye axis, thereby controlling the progression of myopia.

AI-FUNDUSCAMERA-P

Our AI-FUNDUSCAMERA-P is a portable, automatic and self-service fundus camera that can easily apply to any healthcare environments, which is a breakthrough innovation from existing fundus cameras. Our products are operator-free and can complete the retinal image capture automatically while traditional fundus cameras require professionals to operate. We received a Class II medical device certificate from the Shanghai branch of the NMPA for our AI-FUNDUSCAMERA-P in March 2021 and had commenced commercialization since then.

獨有的硬件設備

我們擁有三款自主研发的可適配我們輔助診斷SaMD及健康風險評估解決方案的眼底相機，從而使我們可以提供硬件和軟件相結合的醫療健康服務整體解決方案。配合我們的軟件產品，我們的硬件設備由設備內置的人工智能技術驅動，例如語音識別、語音合成及計算機視覺，可以更低的成本成功解決市場上現有眼底相機的痛點。此外，我們推出了一款近視控制儀，載入了我們自己的人工智能算法，用於動態實時追蹤。該設備通過低強度光反復照射眼底，增加脈絡膜的厚度，抑制眼軸的過度增長，從而控制近視加深。

AI-FUNDUSCAMERA-P

我們的AI-FUNDUSCAMERA-P是一款便攜、自動及自助的眼底相機，可以方便用於任何醫療健康場景，是對現有眼底相機的突破性創新。我們的產品無需操作人員，能夠自動完成視網膜影像採集，而傳統眼底相機則需專業人士操作。我們的AI-FUNDUSCAMERA-P於2021年3月獲得上海市藥監局第二類醫療器械證書，並自那時起開始商業化。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

AI-FUNDUSCAMERA-D

Our AI-FUNDUSCAMERA-D is a fully automatic and fully self-service desktop fundus camera with comparable image quality but significantly lower costs than traditional high-end desktop fundus cameras. Its infrared imaging and low-light enhancement technologies facilitate the capture of high-quality images. We received the Class II medical device registration certificate for our AI-FUNDUSCAMERA-D from the Shanghai branch of the NMPA in July 2022. We kick-started the commercialization of our desktop version in various healthcare environments to meet the customer's needs for large-sized fundus cameras.

AI-FUNDUSCAMERA-M

Our AI-FUNDUSCAMERA-M is a multimodal health scanner integrated with more biosensors that not only enable it to capture retinal images but also allows for the possibility to obtain other physiological data, such as electrocardiograms, blood oxygen and blood pressure. The collection of multimodal physiological data serves as the foundation of our AI-based health risk assessment solutions. We are in the process of applying the license for this product and are expected to obtain the approval by the end of 2023.

AI-FUNDUSCAMERA-D

我們的AI-FUNDUSCAMERA-D是一款全自動自助的台式眼底相機，其影像品質可比擬傳統高端台式眼底相機，但成本卻大幅低於傳統高端台式眼底相機。其紅外影像及弱光增強技術便於捕提高品質圖像。我們的AI-FUNDUSCAMERA-D於2022年7月獲得上海市藥監局第二類醫療器械註冊證書。我們將在多類醫療健康場景中開始我們台式版本的商業化，以滿足客戶對大型眼底相機的需求。

AI-FUNDUSCAMERA-M

我們的AI-FUNDUSCAMERA-M是一款整合了更多生物傳感器的多模態健康掃描儀，它不僅可以捕捉視網膜影像，還可能用以獲取其他生理數據，如心電圖、血氧和血壓。收集多模態生理數據是我們的人工智能健康風險評估解決方案的基礎。我們正就本產品申請許可證並預期於2023年底獲得批准。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

WARNING UNDER RULE 18A.08(3) OF THE LISTING RULES: WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET OUR CORE PRODUCT, AIRDOC-AIFUNDUS.

Our R&D and Technologies

According to the latest “China Cardiovascular Health and Disease Report in 2022”, cardiovascular disease is the “number one killer” in China, accounting for 48% of fatalities in urban area. In other words, roughly 2 out of every 5 deaths are caused by cardiovascular disease. Traditional diagnosis methods for ICVD start with the collection of data such as blood pressure, blood lipids and body mass index, which are then analyzed using regression models to assess cardiac conditions. However, this process can be time-consuming. The use of fundus imaging combined with AI algorithm would expedite results, offering a quick, non-intrusive, convenient and cost-efficient alternative.

In 2023, China’s national population growth rate declined by 0.6%, indicating an accelerating trend towards an aging population. In response, we are allocating more resources to the identification of aging-associated diseases. We have partnered with Peking University (北京大學) to explore the possibilities of early detection of dementia. Utilizing our AI-empowered fundus camera, dementia can be easily detected in a quicker, non-invasive, convenient and cost-effective manner. The commercialization of this technology brings our products an opportunity to reach a larger community. Early detection will help to lower the medical costs and alleviate the social burden.

上市規則第18A.08(3)條規定的警示聲明：我們可能最終無法開發及銷售我們的核心產品 AIRDOC-AIFUNDUS。

我們的研發及技術

根據最新發佈的《中國心血管健康與疾病報告2022》，心腦血管疾病是中國的「頭號殺手」，佔城市死亡人數的48%。換言之，大約每5個死亡個案中就有2人死於心腦血管疾病。傳統的ICVD診斷方法以收集血壓、血脂及體重指數等數據為開端，然後使用回歸模型進行分析，以評估心臟狀況。然而，此過程非常耗時。而使用眼底成像與人工智能算法相結合將加快結果產出，提供一個快速、無創、便捷且具成本效益的替代方法。

於2023年，中國全國人口增長率下降0.6%，表明人口老齡化趨勢加快。為此，我們正投入更多資源以識別老齡化疾病。我們已與北京大學合作以探索早期發現癡呆症的可能性。使用我們的人工智能眼底相機可以更快、無創、便捷及具成本效益的方式較易檢測癡呆症。此項技術的商業化為我們的產品帶來良機，以惠及更多社區。早期檢測將有助於降低醫療成本並減輕社會的負擔。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

With evolution of technology and the rising popularity of online learning in recent years, children are spending more time on mobile devices. This trend has led to an earlier onset of myopia among adolescence and children and therefore we focus more on preventing and controlling myopia among them. By allocating resources to R&D in these two areas leveraging our AI-empowered optical technologies, we initiated the commercialization of two new products in 2023. We stayed tuned to large language model (LLM) technologies and put significant R&D efforts in this area to enhance our existing pipeline and to integrate comprehensive AI-based treatment solutions to our existing diagnosis technologies. This advancement represents the next phase of our strategy, extending our products and services from diagnosis and detection to treatment.

We are also in the process of registering the license for the AI-FUNDUSCAMERA-M to its new version, which will allow us to incorporate additional modules for diagnosing different types of potential diseases. It is expected to be a new breakthrough for our fundus camera as it will enable us to pre-screen for a broader range of diseases.

In the first half of 2023, we were granted 47 new patents, including 25 inventions, 12 utility models, and 10 appearance designs. To date, we have 190 patents, of which 91 are inventions, 39 are utility models, and 60 are appearance designs, and possess 79 software copyrights.

近年來，隨著技術的發展及在線學習的日漸普及，兒童於移動設備上消耗的時間越來越多。這一趨勢導致青少年及兒童近視的發病年齡提前，因此我們更關注彼等近視的防控。通過利用我們的人工智能光學技術將資源分配予這兩個領域的研發，我們於2023年啟動了兩款新產品的商業化。我們一直關注大語言模型(LLM)技術並在該領域投入大量研發力量，以加強我們的現有管線，並將全面的人工智能治療解決方案整合至我們現有的診斷技術中。這一進步代表我們下一階段的戰略，將我們的產品及服務由診斷及檢測延伸至治療。

我們亦正在為AI-FUNDUSCAMERA-M提交註冊申請至其全新版本，該產品將使我們能夠納入額外模塊，用於診斷不同類型的潛在疾病。該產品預期將成為我們眼底相機的全新突破，因為該產品將使我們能夠對更廣泛的疾病進行預掃描。

2023年上半年，我們獲得47項新專利，包括25項發明、12項實用新型及10項外觀設計。迄今為止，我們擁有專利190項，其中發明91項、實用新型39項及外觀設計60項，亦擁有79項軟件版權。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Commercialization Development

Our portfolio of AI-empowered retina-based early detection, diagnosis and health risk assessment solutions has potentially broad applications and coverage of a wide range of chronic diseases. Given the wide range of healthcare scenarios that can use our products, we have developed a flexible and multi-channel sales and marketing strategy to cover various commercialization pathways in medical institutions, consumer healthcare environments and eye health management settings.

During the Reporting Period, the number of service sites utilizing our SaMDs and health risk assessment solutions increased year-over-year to 3,331 from 2,681. For our provision of SaMDs or health risk assessment solutions, we charge our customers on a pay-per-use basis based on the actual amount of testing services we provided. For the Reporting Period, we charged an average of RMB20.87 per Use, which is calculated by dividing our revenue from the provision of AI-based software solutions by the Uses, representing a year-over-year increase of 8.1% from RMB19.3 per Use for the same period in 2022.

We had established a marketing team of 103 members as of June 30, 2023 to provide our customers with a full life cycle of customized supports. Our sales and marketing team which comprises functions of sales, product solution and customer success covers different geographic regions and different commercialization channels. In order to facilitate more sales to capture market share, we provide our sales and marketing personnel with comprehensive training covering our corporate culture, product knowledge, medical theories and marketing system, etc.

商業化發展

我們的產品組合基於人工智能視網膜影像識別技術，提供早期檢測、診斷及健康風險評估解決方案，有潛力覆蓋廣泛的應用場景及多種慢性疾病。由於多種醫療健康場景均可使用我們的產品，我們開發出一套靈活、多渠道的銷售及營銷策略以涵蓋醫療機構、大健康場景及眼健康管理場景的多種商業化渠道。

於報告期內，使用我們的SaMD及健康風險評估解決方案的服務網點數量從2,681個同比增加至3,331個。就我們提供的SaMD或健康風險評估解決方案而言，根據我們提供檢測服務的實際用量，我們向客戶按次收費。於報告期內，我們平均每次檢測收費為人民幣20.87元（通過提供人工智能軟件解決方案的收入除以檢測次數計算得出），較2022年同期的每次檢測人民幣19.3元同比增長8.1%。

截至2023年6月30日，我們建立了一支由103名成員組成的營銷團隊，為客戶提供全生命週期的定製化支持。我們的銷售及營銷團隊由銷售、產品解決方案和客戶成功等職能組成，覆蓋不同地理區域及商業化渠道。我們為銷售及營銷人員提供全面培訓，包括企業文化、產品知識、醫學理論及營銷體系等以促進更多的銷售以搶佔市場份額。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Production Capability

Cost control and quality assurance have always been crucial to us. Initially, we only had one factory located in Beijing. In 2022, we commenced to construct our second manufacture facility in the High-tech Development Zone of Changsha, Hunan. In the same year, our Changsha factory obtained the Medical Device Production License (醫療器械生產許可證) and was ready to commence production. We expect to receive ISO13485 medical device quality management system certification in 2023. Our factory implements the 6S Lean Management System and the ERP production management system, ensuring production efficiency and compliance with all required safety measures. Operated by production professionals, the Changsha factory currently has six production lines manufacturing three types of devices, with an annual production capacity of approximately 100,000 fundus camera per year. With this Changsha factory setup, we are able to enhance cost and quality control, and believe our competitive advantages will continue going forward.

Airdoc Medical

Airdoc Medical covers medical institutions which include hospitals, primary healthcare institutions (such as community clinics) and health checkup centers. Aiming to be of great help to eye doctors and address the issue of lack of experienced retinal specialists in underserved regions, our solution for Airdoc Medical primarily serves the clinical needs for detection and auxiliary diagnosis of certain indications with quantitative measurements, such as the total size and number of hemorrhages and exudates.

生產力

成本控制及質量保證對我們而言一直至關重要。最初，我們僅在北京有一個工廠，2022年，在湖南長沙高新技術開發區，我們開始建造第二個製造基地，並在當年獲得了醫療器械生產許可證，開始投產。我們預計於2023年獲得ISO13485醫療器械質量管理體系認證。我們的工廠採用6S精益管理體系及ERP生產管理系統，確保生產效率並符合所有必須的安全措施。長沙工廠由專業生產人員營運，目前有六條生產線製造三種類型的設備，年生產力約為每年100,000台眼底相機。通過設立長沙工廠，我們能夠加強成本及質量控制並相信我們於未來將繼續保持競爭優勢。

鷹瞳醫療

鷹瞳醫療覆蓋包括醫院、基層醫療機構（如社區診所）及體檢中心在內的醫療機構。為了成為眼科醫生的極大助力，解決醫療資源欠缺地區資深視網膜專家數量不足的問題，我們鷹瞳醫療的解決方案主要滿足檢測及輔助診斷某些適應症的臨床需求，提供諸多定量測量指標，如出血及滲出總面積及數量。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

For our sales to hospitals, we seek to include our Airdoc-AIFUNDUS (1.0) in the pricing guidance in most provinces in China, upon which hospitals can charge patients separately for such medical service. As of the date of this report, the pricing guidance related to our products had been issued by local governmental authorities in Beijing, Hebei, Shandong, Shanxi, Anhui and Jiangsu, pursuant to which our Airdoc-AIFUNDUS can be utilized as a new charging item. We are currently working on assisting several hospitals across multiple provinces, including Sichuan, Guangdong, Shaanxi, Jiangxi, Jilin and Yunan to review the pricing mechanism. For primary healthcare institutions and health checkup centers, we also market our health risk assessment solutions as we see strong opportunities there.

We are dedicated to increasing our penetration in hospitals across the country while expanding our coverage of primary healthcare institutions which represents a big portion of medical institutions in China. During the Reporting Period, we sold our Airdoc-AIFUNDUS (1.0) to 143 hospitals and 525 primary healthcare institutions. In addition, we also implemented our AI-based solutions in over 210 health checkup centers across China. For the first six months of 2023, we recorded revenue of RMB29.8 million from Airdoc Medical through the sales of our Airdoc-AIFUNDUS (1.0) retina camera.

對於面向醫院的銷售，我們致力將Airdoc-AIFUNDUS (1.0)納入中國大部分省份的定價指引，據此，醫院可就該等醫療服務向患者單獨收費。截至本報告日期，北京、河北、山東、山西、安徽及江蘇的地方政府機關已發佈我們產品相關的定價指引，據此，我們的Airdoc-AIFUNDUS可作為新增收費項目。我們目前正在協助包括四川、廣東、陝西、江西、吉林及雲南在內的多個省份的若干醫院審閱定價機制。對於基層醫療機構及體檢中心而言，由於我們謹此預見到巨大機遇，因此亦向其銷售我們的健康風險評估解決方案。

我們致力於提高在全國醫院的滲透率，同時擴大我們對基層醫療機構的覆蓋，因為國內大部分醫療機構都是基層醫療機構。於報告期內，我們已將Airdoc-AIFUNDUS (1.0)銷售給143家醫院及525家基層醫療機構。此外，全國超過210個體檢中心部署了我們的人工智能解決方案。於2023年首六個月，我們通過銷售Airdoc-AIFUNDUS (1.0)視網膜相機，來自鷹瞳醫療的收入達到人民幣29.8百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Airdoc Health

Airdoc Health covers a wide range of consumer healthcare environments, such as insurance companies and pharmacies, to which we offer our health risk assessment solutions that focus on chronic diseases. As the concept of health management is on the rise, more types of business settings have emerged as the entry point of daily health management for specific populations, and they are keen to better serve their end users' specific healthcare needs. This is where we can perfectly fit in. We empower consumer healthcare environments to provide the AI-enabled assessment of risk factors for chronic diseases and continuous health monitoring, allowing high-quality healthcare accessible in a much wider range of business settings and to a much larger base of end users.

In the business setting of insurance, we assist insurance companies in evaluating the health conditions of their insurance applicants and insured members in an accurate, efficient and continuous manner. During the Reporting Period, we had provided our solutions to top commercial insurance companies such as Taikang Life Insurance Company Limited, Ping An Insurance Group Co of China Ltd., China Life Insurance Company Limited and New China Life Insurance Co., Ltd. For the Reporting Period, we recorded revenue of RMB21.7 million from Airdoc Health.

鷹瞳健康

鷹瞳健康覆蓋了眾多大健康場景，如保險公司及醫藥公司，我們向該客戶群體提供聚焦於慢性疾病的健康風險評估解決方案。隨著健康管理理念的興起，越來越多類型的商業場景湧現出來成為特定人群日常健康管理的入口，該等商業場景也急於更好地滿足其終端用戶特定的健康服務需求。這正是我們可以完美適應的地方。我們賦能大健康場景以提供人工智能驅動的慢性疾病風險因素評估及健康持續監測服務，從而讓更多的終端用戶在更多的商業場景下可以享受到高品質的健康服務。

在保險業務場景下，我們協助保險公司準確、高效及持續地評估其投保人及受保人的健康狀況。於報告期內，我們為包括泰康人壽保險股份有限公司、中國平安保險(集團)股份有限公司、中國人壽保險股份有限公司及新華人壽保險股份有限公司在內的頂尖商業保險公司提供解決方案。於報告期內，我們來自鷹瞳健康的收入達到人民幣21.7百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Airdoc Eye Health

Airdoc Eye Health covers various eye health management settings, such as optometry centers and government sponsored vision screening projects, to which we offer our health risk assessment solutions that focus on retinal conditions and eye diseases. Myopia control and prevention in particular has become not only a national campaign promoted by the government, but also an activity that parents would prioritize to conduct as their children are facing with more screentime from the extensive use of mobile devices. Through our solution of Airdoc Eye Health, we are keen to address the needs for eye health evaluation as well as myopia control and prevention for the young generation. We plan to launch AI-generated solutions for adolescents, combining big data with our myopia control device to predict myopia conditions and recommend treatment plans. This initiative aligns with our one stop strategy from detection to treatment. For optometry centers, we provide our customers with a comprehensive analysis of their end customers' retinal conditions, enabling them not only to identify risk factors that may lead to impaired vision, but also provide customized professional eyeglasses prescriptions. During the Reporting Period, our solutions were deployed in over 1,250 optometry centers across China through our effective distributors. The number of service sites covered was 1,371 increased year-over-year by over 34.7%. For the Reporting Period, we recorded revenue of RMB31.0 million from Airdoc Eye Health strategy. This new business division is expected to create synergies and additional value and benefit our overall business operations in the long run.

鷹瞳眼健康

鷹瞳眼健康覆蓋各類眼健康管理場景，如視光中心及政府贊助視力篩查項目，我們向該客戶群體提供聚焦於視網膜狀況和眼病的健康風險評估解決方案。尤其是近視防控，不僅已經成為政府倡導的全國性活動，也是家長在孩子大量使用移動設備而面臨屏幕時間增加時會優先考慮的問題。通過鷹瞳眼健康解決方案，我們致力於滿足年輕一代對眼健康評估及近視防控的需求。我們計劃通過結合大數據及近視控制儀，推出針對青少年的生成式人工智能解決方案，以預測近視狀況並推薦治療方案。該舉措符合我們從檢測到治療的一站式策略。就視光中心而言，我們向客戶提供針對其終端客戶視網膜狀況的全面分析，使其不僅能夠識別可能導致視力受損的風險因素，亦能提供定製化專業配鏡處方。於報告期內，通過我們有效的分銷商，我們的解決方案已在中國超過1,250家視光中心部署。所覆蓋的服務網點數量為1,371個，同比增長超過34.7%。於報告期內，我們錄得來自鷹瞳眼健康策略的收入為人民幣31.0百萬元。此新業務部門預期將創造協同效應並帶來額外價值，且使我們的整體業務營運長期受益。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Future and Outlook

In 2023, we target to continue the expansion of our sales channels, aiming for a significant boost in sales growth across Airdoc Medical, Airdoc Health and Airdoc Eye Health. We aim to continue increasing our sales by integrating large language model (LLM) technologies into our main service process. Furthermore, we plan to introduce new business initiatives by combining diagnosis and treatment services for myopia, strabismus and amblyopia, outlining our future strategy. We have fully prepared for a comprehensive entry into the European market. We believe our products will be well accepted by overseas markets as a result of our continued efforts to expand our business footprints in other jurisdictions, such as Malaysia, Singapore, Thailand, United Arab Emirates and South Africa. We expect that sales from these new markets will gradually increase in 2023.

Artificial General Intelligence (AGI) is the trend of the moment, with its applications becoming increasingly integrated into everyday life. We continue to invest in the R&D of AGI-related technologies by further incorporating it into our products and services. We are actively formulating strategies to introduce AGI in our auxiliary diagnosis, disease detection and personalized medical advices, bridging doctors and patients conveniently and efficiently without constraints of time and space.

With our Changsha factory commencing production, we believe our AIFUNDUSCAMERA-P will gain competitive advantages in terms of cost. The expanded capacity will enable us to massively roll out our AIFUNDUSCAMERA-P into different sales channels. At the same time, we will continue to streamline cost, improve gross profit margins, and minimize loss. Going forward, we will continue committing to enhancing production capacity and launching next-generation products that are “accessible and affordable to everyone”.

未來及前景

於2023年，我們的目標為繼續拓寬我們的銷售渠道，力爭大幅提升鷹瞳醫療、鷹瞳健康及鷹瞳眼健康的銷售增長。我們力爭通過將大語言模型(LLM)技術融入我們的主要服務流程，繼續提高銷售額。此外，我們計劃通過結合近視、斜視及弱視的診斷及治療服務推出新業務舉措以勾畫我們的未來戰略。我們已為全面進入歐洲市場做充分準備。由於我們不斷努力擴大我們於其他地區的業務足跡，如馬來西亞、新加坡、泰國、阿拉伯聯合酋長國及南非，我們相信我們的產品將獲海外市場接納。我們預計於2023年該等新市場的銷售額將逐步增加。

通用人工智能(AGI)是當下的趨勢，其應用日益融入日常生活。我們持續投入AGI相關技術研發，將其進一步納入我們的產品及服務。我們正積極制定戰略，於輔助問診、疾病檢測及個性化醫療建議中引入AGI，方便高效地連接醫生及患者，且不受時間及空間限制。

隨著長沙工廠投產，我們認為我們的AIFUNDUSCAMERA-P於成本方面將具有競爭優勢。擴大產能將使我們能夠於不同渠道大規模推廣AIFUNDUSCAMERA-P。同時，我們將繼續精簡成本，提高毛利率，並將損失降至最低。展望未來，我們將繼續致力於提高產能，並推出「讓健康無處不在」的下一代產品。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

FINANCIAL REVIEW

Revenue

During the Reporting Period, we primarily generated revenue from provision of AI-based software solutions, which represented our provision of SaMD and health risk assessment solutions to medical institutions and healthcare providers, including hospitals, community clinics, health checkup centers, insurance companies, optometry centers and pharmacies. We also generated revenue from the sales of hardware devices, representing the fundus cameras we sold together with our software. Depending on customer needs, we may sell our software as a standalone product or as a bundle with hardware developed by us or third parties.

Our revenue increased by 120.6% from RMB37.4 million for the six months ended June 30, 2022 to RMB82.5 million for the six months ended June 30, 2023. The increase is primarily attributable to (i) a 137% year-over-year increase in the business of Airdoc Medical, resulting from a growth in coverage of hospitals and primary healthcare institutions; and (ii) the revenue generated from our myopia treatment products.

Cost of Sales

Our cost of sales primarily consists of (i) employee benefits expenses; (ii) hardware devices costs, representing the cost of sales of in-house fundus camera and in-house myopia treatment products, and the purchase cost of fundus cameras from third parties. We provide integrated healthcare solutions that combine hardware and software and do not sell hardware devices separately to our customers; (iii) depreciation expenses primarily relate to the depreciation of hardware devices; and (iv) cloud service fees, representing the service fees we paid to cloud service suppliers to support our AI-based software solutions.

財務回顧

收入

於報告期內，我們的收入主要來源於提供人工智能軟件解決方案，即我們向醫療機構及醫療健康供應商提供SaMD及健康風險評估解決方案（包括醫院、社區診所、體檢中心、保險公司、視光中心及藥房）。我們的收入亦來源於銷售硬件設備（即連同我們的軟件一起銷售的眼底相機）。根據客戶需求，我們可將軟件作為單獨產品出售或與我們自研或第三方的硬件捆綁銷售。

我們的收入由截至2022年6月30日止六個月的人民幣37.4百萬元增加120.6%至截至2023年6月30日止六個月的人民幣82.5百萬元。該增加主要由於(i)由於醫院及基層醫療機構的覆蓋率均有所增長，鷹瞳醫療業務同比增長137%；及(ii)我們近視治療產品產生的收入。

銷售成本

我們的銷售成本主要包括(i)僱員福利開支；(ii)硬件設備成本，為內部眼底相機及內部近視治療產品的銷售成本，以及從第三方購買眼底相機的成本。我們提供硬件和軟件相結合的醫療健康服務整體解決方案，不單獨向客戶銷售硬件設備；(iii)折舊開支，主要與硬件設備折舊有關；及(iv)雲服務費用，為我們向雲服務供應商支付的用以支持人工智能軟件解決方案的服務費。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Our cost of sales increased by 103.0% from RMB15.3 million for the six months ended June 30, 2022 to RMB31.1 million for the six months ended June 30, 2023, which is primarily due to (i) increase in sales of our hardware devices and related accessories as we commence mass production for our in-house fundus cameras and myopia treatment products; (ii) an increase in operating expenses as a result of the increase in number of our service sites; and (iii) the increase in the cost of cloud services for higher number of cases we detected during the Reporting Period.

Gross Profit and Gross Profit Margin

Based on the factors described above, the gross profit of the Group increased from RMB22.1 million for the six months ended June 30, 2022 to RMB51.4 million for the six months ended June 30, 2023. Gross profit margin is calculated as gross profit divided by revenue. The overall gross profit margin of the Group increased from 59.0% for the six months ended June 30, 2022 to 62.3% for the six months ended June 30, 2023, primarily attributable to the increase in revenue and the improvement in operational efficiency as well as a substantial increase in gross profit margin of our in-house fundus cameras compared to the ones purchased from third parties.

Other Income and Gains

Our other income and gains increased from RMB28.6 million for the six months ended June 30, 2022 to RMB49.8 million for the six months ended June 30, 2023, primarily attributable to improved returns from treasury management.

我們的銷售成本由截至2022年6月30日止六個月的人民幣15.3百萬元增加103.0%至截至2023年6月30日止六個月的人民幣31.1百萬元，主要由於(i)隨著我們開始量產我們的內部眼底相機及近視治療產品，我們的硬件設備及相關配件的銷售額增加；(ii)運營開支因服務網點數量增加而增加；及(iii)我們於報告期內檢出的更多病例導致雲服務成本增加。

毛利及毛利率

根據上述因素，本集團毛利由截至2022年6月30日止六個月的人民幣22.1百萬元增加至截至2023年6月30日止六個月的人民幣51.4百萬元。毛利率按毛利除以收入計算。本集團整體毛利率由截至2022年6月30日止六個月的59.0%增加至截至2023年6月30日止六個月的62.3%，主要由於收入增加及運營效率提升，以及相較於從第三方購買的相機，我們內部眼底相機的毛利率大幅增加。

其他收入及收益

我們的其他收入及收益由截至2022年6月30日止六個月的人民幣28.6百萬元增加至截至2023年6月30日止六個月的人民幣49.8百萬元，主要由於資金管理回報提高所致。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

R&D Expenses

Our R&D expenses primarily consist of (i) employee benefits expenses for our employees involved in R&D; (ii) product development expenses, including expenses incurred for AI studies, R&D activities, technical services, medical equipment and testing services; (iii) product registration expenses; (iv) depreciation expenses in relation to our R&D equipment and facilities; and (v) others, which primarily include leasing expenses for our R&D facilities, travel expenses, utilities expenses and other general office expenses for R&D activities. The following table summarizes a breakdown of our R&D expenses for the periods indicated.

研發開支

我們的研發開支主要包括(i)研發僱員的僱員福利開支；(ii)產品開發開支，包括人工智能研究、研發活動、技術服務、醫療設備及測試服務產生的開支；(iii)產品註冊開支；(iv)與我們的研發設備和設施有關的折舊開支；及(v)其他，主要包括我們研發設施的租賃開支、研發活動相關的差旅開支、水電費及其他一般辦公開支。下表概列於所示期間我們的研發開支明細。

Six months ended June 30, 截至6月30日止六個月

		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Employee benefits expenses	僱員福利開支	39,809	47,771
Product development expenses	產品開發開支	8,529	13,549
Product registration expenses	產品註冊開支	3,175	4,451
Depreciation expenses	折舊開支	3,195	2,171
Others	其他	1,809	1,631
Total	合計	<u>56,517</u>	<u>69,573</u>

Our R&D expenses decreased by 18.8% from RMB69.6 million for the six months ended June 30, 2022 to RMB56.5 million for the six months ended June 30, 2023, primarily due to the decrease in employee benefits expenses as we continue to streamline corporate operations and prioritize targeted R&D activities.

我們的研發開支由截至2022年6月30日止六個月的人民幣69.6百萬元減少18.8%至截至2023年6月30日止六個月的人民幣56.5百萬元，主要由於僱員福利開支減少所致，因為我們持續簡化公司運營並優先考慮有針對性的研發活動。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Selling and Distribution Expenses

Our selling and distribution expenses primarily consist of employee benefits expenses for our in-house sales and marketing team and marketing expenses.

Our selling and distribution expenses decreased by 9.3% from RMB48.9 million for the six months ended June 30, 2022 to RMB44.3 million for the six months ended June 30, 2023, primarily due to the decrease in employee benefits expenses, meanwhile partially offset by the increase in marketing expenses as a result of our business growth.

Administrative Expenses

Our administrative expenses mainly consist of employee benefits expenses for our employees involved in administrative and supportive functions and professional service expenses.

Our administrative expenses increased by 28.0% from RMB31.7 million for the six months ended June 30, 2022 to RMB40.6 million for the six months ended June 30, 2023, primarily due to the adoption of a new employee equity incentive plan.

Income Tax

We recorded income tax of RMB488,000 for the six months ended June 30, 2023 (June 30, 2022: nil).

銷售及分銷開支

我們的銷售及分銷開支主要包括我們內部銷售及營銷團隊的僱員福利開支及營銷開支。

我們的銷售及分銷開支由截至2022年6月30日止六個月的人民幣48.9百萬元減少9.3%至截至2023年6月30日止六個月的人民幣44.3百萬元，主要由於僱員福利開支的減少，同時部分被我們業務增長導致的營銷開支增加所抵銷。

行政開支

我們的行政開支主要包括我們行政管理和支持職能僱員的僱員福利開支及專業服務開支。

我們的行政開支由截至2022年6月30日止六個月的人民幣31.7百萬元增加28.0%至截至2023年6月30日止六個月的人民幣40.6百萬元，主要由於採納新僱員股權激勵計劃所致。

所得稅

截至2023年6月30日止六個月，我們錄得所得稅人民幣488,000元（2022年6月30日：無）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Loss for the Period

We recorded a loss of RMB41.0 million for the six months ended June 30, 2023, compared with a loss of RMB99.7 million for the six months ended June 30, 2022. Our loss for the period significantly narrowed by 58.9%, which is mainly attributable to (i) the continuous improvement in our operational efficiency; (ii) the significant increase in our revenue; and (iii) the improvement in the gross profit margin due to enhanced cost control.

Property, Plant and Equipment

Our property, plant and equipment primarily consist of (i) hardware devices, representing fundus cameras which have been deployed or will be deployed at our customers' service site to be used together with our software; (ii) furniture and others; and (iii) leasehold improvement.

Our property, plant and equipment decreased to RMB16.8 million as of June 30, 2023 from RMB24.2 million as of December 31, 2022, which was primarily due to an increase in depreciation of our hardware devices.

Inventories

Our inventories primarily consist of raw materials for manufacturing our in-house fundus cameras and the third party fundus cameras we purchased for the bundled sales together with our software and in-house myopia treatment products. We assign specific personnel to regularly monitor our inventories and endeavor to keep an optimal inventory level in line with the expected usages in the near term.

Our inventories increased to RMB54.6 million as of June 30, 2023 from RMB29.6 million as of December 31, 2022, which was primarily due to the stockpiling for raw material inventory to support the manufacture and sales of our in-house fundus cameras and myopia treatment products.

期內虧損

我們於截至2023年6月30日止六個月錄得虧損人民幣41.0百萬元，而截至2022年6月30日止六個月為虧損人民幣99.7百萬元。我們的期內虧損大幅收窄58.9%，主要由於(i)營運效率持續改善；(ii)收入大幅增加；及(iii)成本控制加強導致毛利率改善。

物業、廠房及設備

我們的物業、廠房及設備主要包括(i)硬件設備，指已部署或將部署在我們客戶的服務網點以配合我們的軟件一同使用的眼底相機，(ii)辦公設備及其他；及(iii)租賃物業裝修。

我們的物業、廠房及設備由截至2022年12月31日的人民幣24.2百萬元減少至截至2023年6月30日的人民幣16.8百萬元，主要由於我們的硬件設備的折舊增加所致。

存貨

我們的存貨主要包括用於製造內部眼底相機的原材料及我們為捆綁銷售我們的軟件及內部近視治療產品而購買的第三方眼底相機。我們指派特定人員定期監控我們的庫存，並致力於維持最佳存貨水平，使之符合近期的預期用量。

我們的存貨由截至2022年12月31日的人民幣29.6百萬元增加至截至2023年6月30日的人民幣54.6百萬元，主要由於儲備原材料庫存用以支持我們內部眼底相機及近視治療產品製造及銷售。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Trade Receivables

Our trade receivables increased to RMB80.8 million as of June 30, 2023 from RMB63.9 million as of December 31, 2022, which is in line with the significant increase in revenue partially offset by a relatively quicker payment collection from our customers.

Prepayments, Other Receivables and Other Assets

Our prepayments, other receivables and other assets increased to RMB27.5 million as of June 30, 2023 from RMB19.4 million as of December 31, 2022, which was primarily due to an increase in prepayments to suppliers in relation to the raw material procurement and consulting services that is in line with our operational scale-up.

Financial Assets at Fair Value Through Profit or Loss

Our financial assets at fair value through profit or loss mainly represented wealth management products subscribed for from certain financial institutions to improve cash utilization efficiency. Our financial assets at fair value through profit or loss increased from RMB126.2 million as of December 31, 2022 to RMB343.3 million as of June 30, 2023, primarily because we invested in certain funds as a supplemental means to improve utilization of our idle cash on a short-term basis.

應收賬款

我們的應收賬款由截至2022年12月31日的人民幣63.9百萬元增加至截至2023年6月30日的人民幣80.8百萬元，該增長與收入的大幅增加一致，部分被我們從客戶相對較快的收款所抵銷。

預付款項、其他應收款項及其他資產

我們的預付款項、其他應收款項及其他資產由截至2022年12月31日的人民幣19.4百萬元增加至截至2023年6月30日的人民幣27.5百萬元，主要由於與原材料採購及諮詢服務相關的供應商預付款項增加，以配合我們營運規模的擴大。

以公允價值計量且其變動計入當期損益的金融資產

我們以公允價值計量且其變動計入當期損益的金融資產指為提高現金使用效率而從若干金融機構認購的理財產品。我們以公允價值計量且其變動計入當期損益的金融資產從截至2022年12月31日的人民幣126.2百萬元增加至截至2023年6月30日的人民幣343.3百萬元，主要是因為我們投資於若干基金作為短期內提高閒置現金使用率的補充措施。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Cash and Cash Equivalents

Our cash and cash equivalents decreased to RMB876.4 million as of June 30, 2023 from RMB1,268.3 million as of December 31, 2022, which was primarily due to the purchase of financial assets, equity investment, and the use of cash in the ordinary course of business during the Reporting Period.

Trade Payables

Our trade payables increased to RMB22.9 million as of June 30, 2023 from RMB6.6 million as of December 31, 2022, which was primarily due to extended payment terms negotiated with our suppliers.

Liquidity and Source of Funding

Our policy is to regularly monitor our liquidity requirements and our compliance with lending covenants, to ensure that it maintains sufficient reserves of cash and adequate committed lines of funding from major financial institutions to meet its liquidity requirements in the short and longer term.

As of June 30, 2023, our current assets were RMB1,408.8 million which mainly includes cash and cash equivalents of RMB876.4 million, time deposits of RMB93.1 million and other financial assets of RMB276.5 million. As of June 30, 2023, our current liabilities were RMB90.3 million which mainly includes trade payables of RMB22.9 million, other payables and accruals of RMB31.4 million and contract liabilities of RMB26.5 million.

現金及現金等價物

我們的現金及現金等價物由截至2022年12月31日的人民幣1,268.3百萬元減少至截至2023年6月30日的人民幣876.4百萬元，主要由於報告期內在購買金融資產、股權投資及日常經營活動中現金使用支出所致。

應付賬款

我們的應付賬款由截至2022年12月31日的人民幣6.6百萬元增加至截至2023年6月30日的人民幣22.9百萬元，主要由於與我們的供應商協商延長付款期限所致。

流動資金及資金來源

我們的政策為定期監控我們的流動資金需求及借貸契諾遵守情況，以確保本集團維持足夠的現金儲備及獲大型金融機構提供充足的承諾資金額度，以應付我們的短期及長期的流動資金需求。

截至2023年6月30日，我們的流動資產為人民幣1,408.8百萬元，其中現金及現金等價物為人民幣876.4百萬元、定期存款為人民幣93.1百萬元以及其他金融資產為人民幣276.5百萬元。截至2023年6月30日，我們的流動負債為人民幣90.3百萬元，其中應付賬款為人民幣22.9百萬元，其他應付款項及應計費用為人民幣31.4百萬元及合約負債為人民幣26.5百萬元。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論與分析

Borrowings

As of June 30, 2023, we did not have any bank loans or other borrowings (as of December 31, 2022: nil).

Contract Liabilities

Our contract liabilities represent our obligations to transfer services to our customers as we entered into services agreements with our customers for AI-based software solutions and sales of hardware devices for which we have received advanced payments from such customers under the relevant customer service agreements or work orders.

Our contract liabilities increased to RMB26.5 million as of June 30, 2023 from RMB18.2 million as of December 31, 2022, which was primarily due to the increase in the advances received from customers for new contracts signed in the first half of 2023.

Net Current Assets

Our net current assets decreased to RMB1,318.6 million as of June 30, 2023 from RMB1,611.2 million as of December 31, 2022.

Gearing Ratio

Gearing ratio is calculated by using interest-bearing borrowings and lease liabilities less cash and cash equivalents, divided by total equity and multiplied by 100%. As of June 30, 2023, we were in a net cash position and thus gearing ratio is not applicable.

Treasury Policy

We adopt a prudent financial management approach for our treasury policy to ensure that our liquidity structure comprising assets, liabilities and other commitments is able to always meet our capital requirements.

借款

截至2023年6月30日，我們概無任何銀行貸款或其他借款(截至2022年12月31日：無)。

合約負債

我們的合約負債是指我們向客戶轉移服務的義務，原因是我們與客戶就人工智能軟件解決方案和硬件設備銷售訂立了服務協議，我們根據相關的客戶服務協議或工作訂單，從該等客戶收取預付款。

我們的合約負債由截至2022年12月31日的人民幣18.2百萬元增加至截至2023年6月30日的人民幣26.5百萬元，主要由於2023年上半年就客戶新簽合約而獲得的預付款增加所致。

流動資產淨值

我們的流動資產淨值由截至2022年12月31日的人民幣1,611.2百萬元減少至截至2023年6月30日的人民幣1,318.6百萬元。

資產負債比率

資產負債比率的計算方法是用有息借款及租賃負債減去現金及現金等價物，除以總權益，再乘以100%。截至2023年6月30日，我們處於淨現金狀況，因此資產負債比率並不適用。

庫務政策

我們就庫務政策採取審慎的財務管理方法，以確保我們由資產、負債及其他承擔組成的流動資金架構能夠始終滿足我們的資金需求。

OTHER INFORMATION 其他資料

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVES' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES AND DEBENTURES OF THE COMPANY OR ANY OF ITS ASSOCIATED CORPORATIONS

As of June 30, 2023, the interests and short positions of the Directors, Supervisors or chief executives of the Company and their associates in any of the Shares, underlying Shares and debentures of our Company or its associated corporation (within the meaning of Part XV of the SFO), as recorded in the register required to be kept by the Company pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code were as follows:

董事、監事和最高行政人員於本公司或其任何相聯法團的股份、相關股份及債權證中的權益及淡倉

截至2023年6月30日，本公司董事、監事或最高行政人員及彼等聯繫人士於本公司或其相聯法團的任何股份、相關股份及債權證（定義見證券及期貨條例第XV部）中，擁有根據證券及期貨條例第352條記錄於本公司須備存的登記冊內之權益及淡倉，或須登記於其所述之登記冊內之權益及淡倉，或根據標準守則須知會本公司及聯交所之權益及淡倉如下：

Interests in Shares or underlying Shares of the Company

於本公司股份或相關股份的權益

Name of Director	Position	Nature of interest	Category of Shares	Number of Shares	Approximate percentage of the relevant category of Shares ⁽¹⁾	Approximate percentage of interest in our Company
董事姓名	職務	權益性質	股份類別	股份數目	相關股份類別的概約百分比 ⁽¹⁾	於本公司的權益概約百分比
Mr. Zhang 張先生	Executive Director and chief executive officer 執行董事兼首席執行官	Beneficial owner	Unlisted Shares	17,248,854 (L)	22.22%	16.65%
		實益擁有人	未上市股份	17,248,854 (L)	22.22%	16.65%
		Beneficial owner ⁽²⁾	H Shares	3,107,040 (L)	11.98%	3.00%
		實益擁有人 ⁽²⁾	H股	3,107,040 (L)	11.98%	3.00%
		Interest in a controlled corporation ⁽³⁾	Unlisted Shares	5,331,308 (L)	6.87%	5.15%
		受控法團權益 ⁽³⁾	未上市股份	5,331,308 (L)	6.87%	5.15%
		Interest of a party to an agreement ⁽⁴⁾	Unlisted Shares	2,796,117 (L)	3.60%	2.70%
協議訂約方權益 ⁽⁴⁾	未上市股份	2,796,117 (L)	3.60%	2.70%		

OTHER INFORMATION

其他資料

Notes:

- (1) The percentage is calculated based on the number of relevant category of Shares in issue as of June 30, 2023.
- (2) As of June 30, 2023, 3,107,040 H Shares underlying the 3,107,040 Incentive Shares were granted to Mr. ZHANG Dalei under the 2022 Equity Incentive Scheme.
- (3) As of June 30, 2023, Mr. Zhang was the general partner of Airdoc Universe. Therefore, Mr. Zhang was deemed to be interested in the Shares held by Airdoc Universe under the SFO.
- (4) As of June 30, 2023, pursuant to the Concert Party Agreement, Mr. Zhang agreed to act in concert with Mr. Gao and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Zhang was deemed to be interested in an aggregate of 2,796,117 Unlisted Shares, consisting of 883,357 Unlisted Shares held by Mr. Gao and 1,912,760 Unlisted Shares held by Mr. Chen under the SFO.
- (5) (L) — Long position

Save as disclosed above, as of June 30, 2023, to the best knowledge of the Company, none of the Directors, Supervisors or chief executives of the Company or their associates had or was deemed to have any interests or short positions in the Shares, underlying Shares or debentures of the Company or any of its associated corporations as recorded in the register required to be kept, pursuant to Section 352 of the SFO, to be recorded in the register referred to therein, or as otherwise required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

附註：

- (1) 該百分比乃根據截至2023年6月30日已發行的相關股份類別數量計算。
- (2) 截至2023年6月30日，根據2022年股權激勵計劃向張大磊先生授予3,107,040股激勵股份相關的3,107,040股H股。
- (3) 截至2023年6月30日，張先生是鬱金香宇宙的一般合夥人。因此，根據證券及期貨條例，張先生被視為於鬱金香宇宙持有的股份中擁有權益。
- (4) 截至2023年6月30日，根據一致行動人士協議，張先生、高先生及陳先生同意在本公司股東大會上通過調整其投票來實現一致行動。因此，根據證券及期貨條例，張先生被視為於合共2,796,117股未上市股份中擁有權益，當中包括高先生持有的883,357股未上市股份及陳先生持有的1,912,760股未上市股份。
- (5) (L) — 好倉

除上文所披露者外，截至2023年6月30日，據本公司所知，概無本公司董事、監事或最高行政人員或彼等聯繫人士於本公司或其任何相聯法團的股份、相關股份或債權證中，擁有根據證券及期貨條例第352條記錄於本公司須備存的登記冊內之權益及淡倉，或須登記於其所述之登記冊內之權益及淡倉，或根據標準守則須知會本公司及聯交所之權益及淡倉。

OTHER INFORMATION 其他資料

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

主要股東於股份及相關股份之權益及淡倉

As of June 30, 2023, so far as the Directors or chief executives of the Company are aware, the following persons (other than the Directors or chief executives of the Company or their associates) had interests and/or short positions in the Shares or underlying Shares as recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

截至2023年6月30日，就本公司董事或最高行政人員所知，以下人士（本公司董事或最高行政人員或彼等聯繫人士除外）擁有根據證券及期貨條例第336條記錄於本公司須備存之登記冊所載之股份或相關股份的權益及／或淡倉：

Interests in Shares or underlying Shares of the Company

於本公司股份或相關股份的權益

Name of Substantial Shareholders 主要股東姓名／名稱	Nature of interest 權益性質	Category of Shares 股份類別	Number of Shares 股份數目	Approximate percentage of the relevant category of Shares 相關股份類別的概約百分比	Approximate percentage of interest in our Company 於本公司的權益概約百分比
Mr. Gao ⁽¹⁾ 高先生 ⁽¹⁾	Beneficial owner 實益擁有人	Unlisted Shares 未上市股份	883,357 (L)	1.14%	0.85%
	Interest of a party to an agreement 協議訂約方權益	Unlisted Shares 未上市股份	24,492,922 (L)	31.55%	23.65%
Mr. Chen ⁽²⁾ 陳先生 ⁽²⁾	Beneficial owner 實益擁有人	Unlisted Shares 未上市股份	1,912,760 (L)	2.46%	1.85%
	Interest of a party to an agreement 協議訂約方權益	Unlisted Shares 未上市股份	23,463,519 (L)	30.22%	22.65%
Fosun International ⁽³⁾ 復星國際 ⁽³⁾	Interest in a controlled corporation 受控法團權益	Unlisted Shares 未上市股份	10,386,756 (L)	13.38%	10.03%
Yadong Beichen ⁽³⁾⁽⁴⁾ 亞東北辰 ⁽³⁾⁽⁴⁾	Beneficial owner 實益擁有人	Unlisted Shares 未上市股份	10,272,503 (L)	13.23%	9.92%
	Interest of a party to an agreement 協議訂約方權益	Unlisted Shares 未上市股份	114,253 (L)	0.15%	0.11%

OTHER INFORMATION

其他資料

Name of Substantial Shareholders 主要股東姓名／名稱	Nature of interest 權益性質	Category of Shares 股份類別	Number of Shares 股份數目	Approximate percentage of the relevant category of Shares 相關股份類別的概約百分比	Approximate percentage of interest in our Company 於本公司的權益概約百分比
Ping An Insurance ⁽⁵⁾ 平安保險 ⁽⁵⁾	Interest in a controlled corporation 受控法團權益	Unlisted Shares 未上市股份	7,169,737 (L) 7,169,737 (L)	9.24% 9.24%	6.92% 6.92%
Ping An Healthtech ⁽⁵⁾ 平安醫療科技 ⁽⁵⁾	Beneficial owner 實益擁有人	Unlisted Shares 未上市股份	7,169,737 (L) 7,169,737 (L)	9.24% 9.24%	6.92% 6.92%
Ms. XU Yanhua ⁽⁶⁾ 徐彥華女士 ⁽⁶⁾	Interest in a controlled corporation 受控法團權益	Unlisted Shares 未上市股份	6,486,253 (L) 6,486,253 (L)	8.25% 8.25%	6.26% 6.26%
Suqian Airdoc ⁽⁶⁾ 宿遷鷹瞳 ⁽⁶⁾	Beneficial owner 實益擁有人	Unlisted Shares 未上市股份	4,166,665 (L) 4,166,665 (L)	5.37% 5.37%	4.02% 4.02%
Tencent Holdings Limited ⁽⁷⁾ 騰訊控股有限公司 ⁽⁷⁾	Interest in a controlled corporation 受控法團權益	Unlisted Shares 未上市股份	5,942,699 (L) 5,942,699 (L)	7.65% 7.65%	5.74% 5.74%
Shiji Sisu ⁽⁷⁾ 世紀思速 ⁽⁷⁾	Beneficial owner 實益擁有人	H Shares H股	5,942,699 (L) 5,942,699 (L)	7.65% 7.65%	5.74% 5.74%
Lake Bleu Capital (Hong Kong) Limited ⁽⁸⁾ 清池資本(香港)有限公司 ⁽⁸⁾	Investment manager 投資經理	H Shares H股	5,049,236 (L) 5,049,236 (L)	19.47% 19.47%	4.88% 4.88%
Lake Bleu Prime ⁽⁸⁾ Lake Bleu Prime ⁽⁸⁾	Beneficial owner 實益擁有人	H Shares H股	3,477,700 (L) 3,477,700 (L)	13.41% 13.41%	3.36% 3.36%
LBC Sunshine ⁽⁸⁾ 清池資本陽光 ⁽⁸⁾	Beneficial owner 實益擁有人	H Shares H股	1,571,536 (L) 1,571,536 (L)	6.06% 6.06%	1.52% 1.52%

OTHER INFORMATION 其他資料

Name of Substantial Shareholders 主要股東姓名／名稱	Nature of interest 權益性質	Category of Shares 股份類別	Number of Shares 股份數目	Approximate percentage of the relevant category of Shares 相關股份類別的概約百分比	Approximate percentage of interest in our Company 於本公司的權益概約百分比
China Life Franklin Asset Management Co., Limited ⁽⁹⁾	Investment manager	H Shares	3,107,000 (L)	11.98%	3.00%
中國人壽富蘭克林資產管理有限公司 ⁽⁹⁾	投資經理	H股	3,107,000 (L)	11.98%	3.00%
China Life Insurance (Group) Company ⁽⁹⁾⁽¹⁰⁾	Beneficial owner	H Shares	155,400 (L)	0.60%	0.15%
中國人壽保險(集團)公司 ⁽⁹⁾⁽¹⁰⁾	實益擁有人	H股	155,400 (L)	0.60%	0.15%
	Interest in a controlled corporation	H Shares	2,951,600 (L)	11.38%	2.85%
	受控法團權益	H股	2,951,600 (L)	11.38%	2.85%
China Life Insurance (Overseas) Company ⁽¹⁰⁾	Beneficial owner	H Shares	2,951,600 (L)	11.38%	2.85%
中國人壽保險(海外)股份有限公司 ⁽¹⁰⁾	實益擁有人	H股	2,951,600 (L)	11.38%	2.85%
SHI Yi ⁽¹¹⁾	Interest in a controlled corporation	H Shares	2,607,336 (L)	10.05%	2.52%
施毅 ⁽¹¹⁾	受控法團權益	H股	2,607,336 (L)	10.05%	2.52%
LAV ImmOn Hong Kong Limited ⁽¹¹⁾	Beneficial owner	H Shares	1,571,536 (L)	6.06%	1.52%
禮安宜申香港有限公司 ⁽¹¹⁾	實益擁有人	H股	1,571,536 (L)	6.06%	1.52%

Notes:

附註：

(1) As of June 30, 2023, pursuant to the Concert Party Agreement, Mr. Gao agreed to act in concert with Mr. Zhang and Mr. Chen by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Gao was deemed to be interested in an aggregate of 24,492,922 Unlisted Shares, consisting of 22,580,162 Unlisted Shares held by Mr. Zhang and 1,912,760 Unlisted Shares held by Mr. Chen under the SFO.

(1) 截至2023年6月30日，根據一致行動人士協議，高先生、張先生及陳先生同意於本公司股東大會上通過調整其投票來實現一致行動。因此，根據證券及期貨條例，高先生被視為於合共24,492,922股未上市股份中擁有權益，其中包括張先生持有的22,580,162股未上市股份及陳先生持有的1,912,760股未上市股份。

OTHER INFORMATION

其他資料

- (2) As of June 30, 2023, pursuant to the Concert Party Agreement, Mr. Chen agreed to act in concert with Mr. Zhang and Mr. Gao by aligning their votes at Shareholders' meetings of the Company. Therefore, Mr. Chen was deemed to be interested in an aggregate of 23,463,519 Unlisted Shares, consisting of 22,580,162 Unlisted Shares held by Mr. Zhang and 883,357 Unlisted Shares held by Mr. Gao under the SFO.
- (2) 截至2023年6月30日，根據一致行動人士協議，陳先生、張先生及高先生同意於本公司股東大會上通過調整其投票來實現一致行動。因此，根據證券及期貨條例，陳先生被視為於合共23,463,519股未上市股份中擁有權益，其中包括張先生持有的22,580,162股未上市股份及高先生持有的883,357股未上市股份。
- (3) As of June 30, 2023, Yadong Beichen was held by Shanghai Ruikun Venture Capital Co., Ltd. (上海銳坤創業投資有限公司) (“**Shanghai Ruikun**”) and Shanghai Fosun Industrial Investment Co., Ltd. (上海復星產業投資有限公司) (“**Shanghai Fosun**”) as to 64.1% and 35.9%, respectively. Shanghai Ruikun was owned as to 98% by Shanghai Fosun High Technology Group Finance Co., Ltd. (上海復星高科技(集團)有限公司) (“**Fosun High Technology**”) which was wholly owned by Fosun International Limited (復星國際有限公司) (“**Fosun International**”), a company whose shares are listed on the Stock Exchange (stock code: 656). Shanghai Fosun was wholly owned by Fosun High Technology. Therefore, each of Shanghai Ruikun, Shanghai Fosun, Fosun High Technology and Fosun International was deemed to be interested in the 10,386,756 Unlisted Shares in which Yadong Beichen was interested under the SFO.
- (3) 截至2023年6月30日，亞東北辰由上海銳坤創業投資有限公司(「上海銳坤」)及上海復星產業投資有限公司(「上海復星」)分別持有64.1%及35.9%的權益。上海復星高科技(集團)有限公司(「復星高科技」)擁有上海銳坤98%的權益，而其本身又由復星國際有限公司(「復星國際」)(一家股份於聯交所上市的公司(股份代號：656))全資擁有。上海復星由復星高科技全資擁有。因此，根據證券及期貨條例，上海銳坤、上海復星、復星高科技及復星國際均被視為於亞東北辰擁有權益的10,386,756股未上市股份中擁有權益。
- (4) As of June 30, 2023, pursuant to the voting proxy arrangement between Ningbo Xingbangyu Business Management Consulting Partnership (Limited Partnership) (寧波星邦鬱企業管理諮詢合夥企業(有限合夥)) (“**Xingbangyu**”) and Yadong Beichen, Xingbangyu conferred the voting right of the Shares held by it on Yadong Beichen. Therefore, Yadong Beichen was deemed to be interested in the 114,253 Unlisted Shares held by Xingbangyu under the SFO.
- (4) 截至2023年6月30日，根據寧波星邦鬱企業管理諮詢合夥企業(有限合夥)(「星邦鬱」)及亞東北辰之間的投票代理安排，星邦鬱將其所持股份的投票權授予亞東北辰。因此，根據證券及期貨條例，亞東北辰被視為於星邦鬱持有的114,253股未上市股份中擁有權益。
- (5) As of June 30, 2023, Ping An Healthtech was wholly owned by Ping An Technology (Shenzhen) Co., Ltd. (平安科技(深圳)有限公司) (“**Ping An Technology**”), which was owned by Ping An Insurance (Group) Company of China, Ltd. (中國平安保險(集團)股份有限公司) (“**Ping An Insurance**”), a company whose shares are listed on the Shanghai Stock Exchange (stock code: 601318), and Shenzhen Ping An Financial Technology Consulting Co., Ltd. (深圳平安金融科技諮詢有限公司) (“**Ping An Financial**”) as to 37.7% and 62.3%, respectively. Therefore, each of Ping An Technology, Ping An Insurance and Ping An Financial was deemed to be interested in the 7,169,737 Unlisted Shares held by Ping An Healthtech under the SFO.
- (5) 截至2023年6月30日，平安醫療科技由平安科技(深圳)有限公司(「平安科技」)全資擁有，而平安科技又由中國平安保險(集團)股份有限公司(「平安保險」)(一家股份於上海證券交易所上市的公司(股份代號：601318))及深圳平安金融科技諮詢有限公司(「平安金融」)分別持有37.7%及62.3%的權益。因此，根據證券及期貨條例，平安科技、平安保險及平安金融均被視為於平安醫療科技持有的7,169,737股未上市股份中擁有權益。

OTHER INFORMATION 其他資料

- (6) As of June 30, 2023, Ms. XU Yanhua (徐彥華), an employee of our Group, was the general partner of Suqian Airdoc and Suqian Zhongyou, each as an employee incentive platform of our Company. Therefore, Ms. XU Yanhua is deemed to be interested in the 4,166,665 and 2,319,588 Unlisted Shares respectively held by Suqian Airdoc and Suqian Zhongyou under the SFO.
- (6) 截至2023年6月30日，本集團僱員徐彥華女士為宿遷鷹瞳及宿遷眾佑（均為本公司僱員激勵平台）的普通合夥人。因此，根據證券及期貨條例，徐彥華女士被視為於宿遷鷹瞳及宿遷眾佑分別持有的4,166,665及2,319,588股未上市股份中擁有權益。
- (7) As of June 30, 2023, Beijing Shi Ji Si Su Technology Co., Ltd. (北京世紀思速科技有限公司) (“**Shiji Sisu**”) was wholly owned by Beijing Sogou Information Service Co., Ltd (北京搜狗信息服務有限公司) (“**Sogou Information**”), which was owned as to 55% and 45% by Guangxi Tencent Venture Capital Co., Ltd. (廣西騰訊創業投資有限公司) (“**Guangxi Tencent**”) and Shenzhen Tencent Computer Systems Company Limited (深圳市騰訊計算機系統有限公司) (“**Tencent Computer**”), respectively. Each of Guangxi Tencent and Tencent Computer is a subsidiary of Tencent Holdings Limited, a company whose shares are listed on the Stock Exchange (stock code: 700). Therefore, each of Sogou Information, Guangxi Tencent, Tencent Computer and Tencent Holdings Limited was deemed to be interested in the 5,942,699 Unlisted Shares held by Shiji Sisu under the SFO.
- (7) 截至2023年6月30日，北京世紀思速科技有限公司（「世紀思速」）由北京搜狗信息服務有限公司（「搜狗信息」）全資擁有，而搜狗信息分別由廣西騰訊創業投資有限公司（「廣西騰訊」）及深圳市騰訊計算機系統有限公司（「騰訊計算機」）擁有55%及45%權益。廣西騰訊及騰訊計算機各自為騰訊控股有限公司（一家股份於聯交所上市的公司（股份代號：700））的附屬公司。因此，根據證券及期貨條例，搜狗信息、廣西騰訊、騰訊計算機及騰訊控股有限公司均被視為於世紀思速持有的5,942,699股未上市股份中擁有權益。
- (8) As of June 30, 2023, Lake Bleu Capital (Hong Kong) Limited was the investment manager of Lake Bleu Prime Healthcare Master Fund Limited (“**Lake Bleu Prime**”) and LBC Sunshine Healthcare Fund II. Limited Partnership (“**LBC Sunshine**”), which held 3,477,700 H Shares and 1,571,536 H Shares, respectively. Therefore, Lake Bleu Capital (Hong Kong) Limited was deemed to be interested in the 5,049,236 H Shares in which Lake Bleu Prime and LBC Sunshine were interested under the SFO.
- (8) 截至2023年6月30日，清池資本（香港）有限公司是Lake Bleu Prime Healthcare Master Fund Limited（「**Lake Bleu Prime**」）和清池資本陽光二號基金（「清池資本陽光」）的投資經理，分別持有3,477,700股H股及1,571,536股H股。因此，根據證券及期貨條例，清池資本（香港）有限公司被視為於Lake Bleu Prime及清池資本陽光擁有權益的5,049,236股H股中擁有權益。
- (9) As of June 30, 2023, China Life Franklin Asset Management Co., Limited was the investment manager of China Life Insurance (Group) Company and China Life Insurance (Overseas) Co., Ltd., which held 155,400 H Shares and 2,951,600 H Shares, respectively. Therefore, China Life Franklin Asset Management Co., Limited was deemed to be interested in the 3,107,000 H Shares in which China Life Insurance (Group) Company and China Life Insurance (Overseas) Co., Ltd. were interested under the SFO.
- (9) 截至2023年6月30日，中國人壽富蘭克林資產管理有限公司為中國人壽保險（集團）公司及中國人壽保險（海外）股份有限公司的投資經理，分別持有155,400股H股及2,951,600股H股。因此，根據證券及期貨條例，中國人壽富蘭克林資產管理有限公司被視為於中國人壽保險（集團）公司及中國人壽保險（海外）股份有限公司擁有權益的3,107,000股H股中擁有權益。

OTHER INFORMATION

其他資料

(10) As of June 30, 2023, China Life Insurance (Overseas) Co., Ltd. was wholly owned by China Life Insurance (Group) Company. Therefore, China Life Insurance (Group) Company was deemed to be interested in the 2,951,600 H Shares held by China Life Insurance (Overseas) Co., Ltd. under the SFO.

(11) As of June 30, 2023, LAV Star Limited was wholly-owned by LAV Fund VI, L.P. and LAV Star Opportunities Limited was wholly-owned by LAV Fund VI Opportunities, L.P. (together with LAV Fund VI, L.P., collectively, the “**LAV Fund VI**”). LAV Star Limited and LAV Star Opportunities Limited were associated with LAV ImmOn Hong Kong Limited. LAV ImmOn Hong Kong Limited and LAV Fund VI were ultimately beneficially owned by Dr. Yi SHI. Therefore, Dr. Yi SHI was deemed to be interested in an aggregate of 2,607,336 H Shares, consisting of 517,900 H Shares held by LAV Star Limited, 517,900 H Shares held by LAV Star Opportunities Limited and 1,571,536 H Shares held by LAV ImmOn Hong Kong Limited, under the SFO.

(12) (L) — Long position

Save as disclosed above, as of June 30, 2023, to the best knowledge of the Company, no person, other than the Directors, Supervisors or chief executives of the Company whose interests are set out in the subsection above, had any interests or short positions in the Shares or underlying Shares as recorded in the register required to be kept under section 336 of the SFO.

(10) 截至2023年6月30日，中國人壽保險(海外)股份有限公司由中國人壽保險(集團)公司全資擁有。因此，根據證券及期貨條例，中國人壽保險(集團)公司被視為於中國人壽保險(海外)股份有限公司持有的2,951,600股H股中擁有權益。

(11) 截至2023年6月30日，LAV Star Limited為LAV Fund VI, L.P.全資擁有，而LAV Star Opportunities Limited由LAV Fund VI Opportunities, L.P. (與LAV Fund VI, L.P.統稱為「**LAV Fund VI**」)全資擁有。LAV Star Limited及LAV Star Opportunities Limited與禮安宜申香港有限公司有關聯。禮安宜申香港有限公司及LAV Fund VI最終由施毅博士實益擁有。因此，根據證券及期貨條例，施毅博士被視為於合共2,607,336股H股中擁有權益，其中包括LAV Star Limited持有的517,900股H股、LAV Star Opportunities Limited持有的517,900股H股及禮安宜申香港有限公司持有的1,571,536股H股。

(12) (L) — 好倉

除上文所披露者外，截至2023年6月30日，據本公司所深知，除本公司董事、監事或最高行政人員(彼等權益載於上文分節中)外，並無任何人士擁有根據證券及期貨條例第336條規定備存之登記冊所載之股份或相關股份的任何權益或淡倉。

OTHER INFORMATION 其他資料

CORPORATE GOVERNANCE

The Company is committed to maintaining high standard of corporate governance to safeguard the interests of the Shareholders, enhance corporate value, formulate its business strategies and policies, and enhance its transparency and accountability.

The Company has adopted the code provisions of the Corporate Governance Code as its own code of corporate governance. The Board is of the view that the Company has complied with all applicable code provisions of the Corporate Governance Code for the Reporting Period, except for the following:

Under the code provision C.2.1 of the Corporate Governance Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Under the current organization structure of the Company, Mr. Zhang is the chairman of the Board, chief executive officer and founder of the Company. With extensive experience in the medical devices industry and having served in the Company since its establishment, Mr. Zhang is in charge of overall management, business and strategic development of the Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer in the same person is beneficial to the business operations and management of the Group. The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. The Board currently comprises four executive Directors (including Mr. Zhang), one non-executive Director and three independent non-executive Directors, and therefore has an independent element in its composition.

The Board will continue to review and monitor the practices of the Company with an aim of maintaining a high standard of corporate governance and assess whether separation of the roles of chairman of the Board and chief executive officer is necessary.

企業管治

本公司致力於維持高水準的企業管治，以維護股東利益、提升企業價值、制定業務策略及政策，並提高透明度及問責性。

本公司已採納企業管治守則之守則條文作為其自身的企業管治守則。董事會認為本公司於報告期已遵守企業管治守則內所有適用守則條文，惟以下情況除外：

根據企業管治守則的守則條文第C.2.1條，主席與首席執行官的角色應分開，不應由同一人擔任。在本公司現有組織架構下，張先生為本公司董事會主席、首席執行官兼創始人。張先生擁有豐富的醫療器械行業經驗，自本公司成立以來一直任職於本公司，負責本集團的整體管理、業務及戰略發展。董事會認為，由同一人兼任董事會主席及首席執行官職務有利於本集團的業務營運及管理。董事會的運作確保權力及授權達到平衡，董事會由經驗豐富且多元化的人士組成。董事會目前由四名執行董事（包括張先生）、一名非執行董事及三名獨立非執行董事組成，因此其組成具備獨立性。

董事會將繼續檢討及監督本公司的運作，以維持高水平的企業管治，並評估董事會主席與首席執行官的角色是否需要有所區分。

OTHER INFORMATION

其他資料

COMPLIANCE WITH THE MODEL CODE

The Company has adopted the Model Code as its own code of conduct regarding dealings in the securities of the Company by the Directors, Supervisors and the Company's senior management who, because of his/her office or employment, is likely to possess inside information in relation to the Company's securities. Having made specific enquiry of all Directors and Supervisors, all of them have confirmed that they have complied with the Model Code during the Reporting Period and up to the date of this interim report. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

COMPLIANCE WITH RELEVANT LAWS AND REGULATIONS

The Group's operations are carried out in the PRC, while its Shares are listed on the Stock Exchange. The businesses operated by the Group are subject to the laws of relevant jurisdiction in the PRC and Hong Kong. During the Reporting Period and up to the date of this interim report, as far as the Board and management are aware, the Group has complied with relevant laws and regulations that have a significant impact on the business and operation of the Group in the applicable jurisdictions.

During the Reporting Period and up to the date of the interim report, none of the Group and the Directors, Supervisors and senior management of the Company were subject to any investigation initiated or administrative penalties imposed by the CSRC, banned from entering the market, identified as inappropriate candidates, publicly condemned by stock exchanges, subject to mandatory measures, transferred to judicial organs or held criminally responsible, and none were involved in any other litigation, arbitration or administrative proceedings which would have a material adverse impact on our business, financial condition or results of operations.

遵守標準守則

本公司已採納標準守則作為董事、監事及本公司高級管理人員在因其職位或僱傭關係而可能擁有有關本公司證券的內幕消息的情況下買賣本公司證券的行為守則。經向全體董事及監事作出具體查詢後，全體董事及監事確認彼等於報告期內及直至本中期報告日期均已遵守標準守則。本公司並無發現可能掌握本公司內幕消息的僱員存在不遵守標準守則的情況。

遵守相關法律法規

本集團於中國開展業務營運，同時股份於聯交所上市。本集團經營的業務須遵守中國及香港相關司法管轄區法律。於報告期內及直至本中期報告日期，就董事會及管理層所知，本集團已遵守對本集團於適用司法管轄區業務及營運有重大影響的相關法律法規。

於報告期內及直至本中期報告日期，概無本集團及董事、監事、本公司高級管理人員受到中國證監會立案調查或行政處罰、被禁止上市、被認定為被證券交易所公開譴責、採取強制措施、移送司法機關或追究刑事責任的不適當人選，並無涉及其他對公司業務、財務狀況或經營業績產生重大不利影響的訴訟、仲裁或行政程序。

OTHER INFORMATION 其他資料

SHARE CAPITAL AND SHARES ISSUED

Details of movements in the share capital of the Company for the six months ended June 30, 2023 and details of the Shares issued for the six months ended June 30, 2023 are set out in Note 18 to the Interim Condensed Consolidated Financial Information.

DEBENTURE ISSUED

The Group did not issue any debenture for the six months ended June 30, 2023.

EQUITY-LINKED AGREEMENTS

No equity-linked agreements that will or may result in the Company issuing shares or that require the Company to enter into any agreements that will or may result in the Company issuing shares were entered into by the Company during the Reporting Period or subsisted at the end of the Reporting Period.

SIGNIFICANT INVESTMENTS, MATERIAL ACQUISITIONS AND DISPOSALS

On January 24, 2023, Airdoc Technology (HK) Limited (“**Airdoc HK**”), a wholly-owned subsidiary of the Company, entered into a subscription agreement with IndexCap Med&Tech I L.P. (the “**Partnership**”) and IndexCap Med&Tech I GP Limited (in its capacity as the general partner of the Partnership), pursuant to which Airdoc HK agreed to (i) subscribe for limited partnership interests in the Partnership for a capital commitment in the amount of US\$14.5 million; and (ii) become a limited partner of the Partnership pursuant to the terms and conditions of the aforesaid limited partnership agreement. Further details of the subscription of interests in the Partnership are set out in the announcement of the Company dated January 24, 2023.

股本及已發行股份

本公司截至2023年6月30日止六個月的股本變動詳情及截至2023年6月30日止六個月已發行股份詳情載於中期簡明綜合財務資料附註18。

已發行債權證

截至2023年6月30日止六個月，本集團未發行任何債權證。

股票掛鈎協議

本公司概無於報告期內訂立或訂立於報告期末仍然存續的、將導致或可能導致本公司發行股份或要求本公司訂立任何協議以導致或可能導致本公司發行股份之股票掛鈎協議。

重大投資、重大收購及出售事項

於2023年1月24日，愛道科技(香港)有限公司(「香港愛道」)(本公司之全資附屬公司)與IndexCap Med&Tech I L.P. (「合夥企業」)及IndexCap Med&Tech I GP Limited (以其作為合夥企業的普通合夥人身份)訂立認購協議，據此，香港愛道同意(i)以資本承擔14.5百萬美元認購合夥企業的有限合夥權益；及(ii)根據上述有限合夥協議的條款及條件，成為該合夥企業的有限合夥人。有關認購合夥企業權益的進一步詳情載於本公司日期為2023年1月24日的公告。

OTHER INFORMATION

其他資料

On May 19, 2023, the Company entered into an equity transfer agreement to acquire the 70% equity interest in Beijing Zhitong Technology Co., Ltd. (北京智瞳科技有限公司) for a cash consideration of RMB182 million. Beijing Zhitong Technology Co., Ltd. is primarily engaged in the R&D, manufacture and sales of ophthalmic medical device and SaMDs. For further details, please refer to the Company's announcements dated May 19, 2023 and June 6, 2023.

Save as disclosed above, we have no other significant investments nor material acquisitions or disposals of subsidiaries and affiliated companies for the Reporting Period.

FUTURE PLANS FOR MATERIAL INVESTMENTS OR CAPITAL ASSETS

As of the date of this interim report, we did not have any existing plan for material investments or acquisition of capital assets.

CAPITAL COMMITMENTS

As of June 30, 2023, we did not have any significant capital commitments (as of December 31, 2022: nil).

CONTINGENT LIABILITIES

As of June 30, 2023, we did not have any contingent liabilities.

CHARGE ON ASSETS

The Company charged a deposit of RMB150.0 million in 2022 to secure the bills of a third party, which was not further substantiated and accordingly the charge was subsequently released on March 24, 2023. Other than the aforesaid, we did not have any charge on assets during the Reporting Period.

於2023年5月19日，本公司訂立一份股權轉讓協議以收購北京智瞳科技有限公司70%的股權，現金代價為人民幣182百萬元。北京智瞳科技有限公司主要從事眼科醫療器械及SaMD的研發、生產及銷售。有關進一步詳情，請參閱本公司日期為2023年5月19日及2023年6月6日的公告。

除上文所披露者外，於報告期內，我們並無進行其他重大投資或重大收購或出售附屬公司及聯屬公司。

重大投資或資本資產的未來計劃

截至本中期報告日期，我們並無任何重大投資或收購資本資產的現有計劃。

資本承擔

截至2023年6月30日，我們概無任何重大資本承擔(截至2022年12月31日：無)。

或有負債

截至2023年6月30日，我們概無任何或有負債。

資產押記

我們於2022年質押了一筆金額為人民幣150.0百萬元的存款，以擔保第三方票據，該事項未被進一步推進，因此押記隨後於2023年3月24日解除。除上述者外，於報告期內，我們概無任何資產押記。

OTHER INFORMATION 其他資料

FOREIGN EXCHANGE EXPOSURE

Our financial statements are expressed in RMB, but certain of its cash and cash equivalents are denominated in foreign currencies, and are exposed to foreign currency risk. We have established a foreign exchange exposure monitoring policy and will consider hedging against significant foreign exchange exposure of the Group should the need arise.

EMPLOYEE AND REMUNERATION POLICIES

As of June 30, 2023, we had 369 full-time employees. The total remuneration cost (share-based compensation included) incurred by the Group for the six months ended June 30, 2023 was RMB98.1 million. The remuneration package of our employees includes salary and bonus, which are generally determined by their qualifications, industry experience, position and performance. We make contributions to social insurance and housing provident funds as required by the PRC laws and regulations. We have adopted the 2022 Equity Incentive Scheme on January 13, 2023 to incentivize our employees.

The Remuneration and Appraisal Committee was set up for reviewing the Company's emolument policy and structure for all remuneration of the Directors, Supervisors and senior management of the Company, having regard to the Company's operating results, individual performance of the Directors, Supervisors and senior management and comparable market practices.

We provide formal and comprehensive company-level and department-level trainings to our new employees, followed by on-the-job training. We also provide trainings and development programs to our employees from time to time to ensure their awareness and compliance with our various policies and procedures.

For the six months ended June 30, 2023, we did not experience any material labor disputes or strikes that may have a material and adverse effect on our business, financial condition or results of operations, or any difficulty in recruiting employees.

外匯風險

我們的財務報表以人民幣表示，但我們的若干現金及現金等價物以外幣計價，並面臨外幣風險。我們已制定外匯風險監控政策，並將在有需要時考慮對沖本集團的重大外匯風險。

僱員及薪酬政策

截至2023年6月30日，我們有369名全職僱員。截至2023年6月30日止六個月，本集團產生的總薪酬成本（包括股份支付）為人民幣98.1百萬元。本公司僱員的薪酬待遇包括薪金及花紅，一般視彼等的資歷、行業經驗、職位及表現而定。我們按照中國法律法規的要求繳納社會保險及住房公積金。我們已於2023年1月13日採納2022年股權激勵計劃以激勵我們的僱員。

本公司設立薪酬與考核委員會，結合本公司經營業績，董事、監事及高級管理人員的個人表現，以及可資比較市場慣例，審議董事、監事及本公司高級管理人員的薪酬政策和薪酬結構。

我們於在職培訓前向新僱員提供正式全面的公司級別與部門級別培訓。我們亦不時為僱員提供培訓及發展規劃，以確保彼等瞭解並遵守我們的各類政策及流程。

截至2023年6月30日止六個月，我們未發生任何可能對我們的業務、財務狀況或經營業績造成重大不利影響的重大勞資糾紛或罷工，亦未在招聘員工方面遇到任何困難。

OTHER INFORMATION

其他資料

USE OF NET PROCEEDS FROM GLOBAL OFFERING

The Company's Shares were listed on the Stock Exchange on November 5, 2021. After finalization and the settlement of the listing expenses, including the relevant expenses incurred by work done by professional parties, the finalized net proceeds from the Global Offering amounted to HK\$1,550.7 million. Accordingly, the planned applications of the net proceeds as disclosed in the section headed "Future Plans and Use of Proceeds" are adjusted pro rata as set forth in the table below. The planned applications and allocation percentage remained unchanged. As of June 30, 2023, approximately HK\$1,105.27 million of the net proceeds of the Global Offering had been utilized as follows:

全球發售所得款項淨額用途

本公司股份於2021年11月5日在聯交所上市。經最終確定及結清上市開支(包括專業人士完成工作所產生的相關開支)後，全球發售的最終所得款項淨額為1,550.7百萬港元。因此，「未來計劃及所得款項用途」一節披露的所得款項淨額的計劃用途已如下表所示按比例調整。計劃中的用途及分配比例維持不變。截至2023年6月30日，全球發售所得款項淨額的約1,105.27百萬港元已作如下用途：

Use of proceeds	所得款項用途	Planned applications (HK\$ million)	Percentage of total net proceeds (%)	Actual usage for the six months ended June 30, 2023 (HK\$ million)	Actual usage up to June 30, 2023 (HK\$ million)	Unutilized net proceeds as of June 30, 2023 (HK\$ million)	Expected time of full utilization of remaining balance
		計劃用途 (百萬港元)	佔所得款項總淨額之百分比(%)	截至2023年6月30日止六個月的實際使用量 (百萬港元)	截至2023年6月30日的實際使用量 (百萬港元)	截至2023年6月30日未動用所得款項淨額 (百萬港元)	餘額悉數動用之預期時間
Optimization, development and commercialization of our Core Product	我們核心產品的優化、開發和商業化	775.4	50%	51.52	195.75	579.65	2026
Research and development and manufacturing of our hardware devices	我們硬件設備的研發和製造	294.6	19%	45.84	103.12	191.48	2026
Ongoing and future R&D of our health risk assessment solutions	我們正在進行的及未來的健康風險評估解決方案的研發	155.1	10%	9.41	45.66	109.44	2026
Development of our portfolio to diversify our AI-empowered retina-based early detection, diagnosis and health risk assessment solutions	我們產品組合的開發，以豐富我們人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案	93.0	6%	8.33	23.48	69.52	2024
Collaborations with academic and research institutions on joint research projects	與學術及研究機構就聯合研究項目進行的合作	77.5	5%	5.20	10.73	66.77	2024
Working capital and other general corporate purposes	營運資金和其他一般公司用途	155.1	10%	20.41	66.69	88.41	2024
Total	合計	1,550.7	100%	140.71	445.43	1,105.27	

OTHER INFORMATION 其他資料

EVENTS AFTER THE REPORTING PERIOD

Save as disclosed herein, there are no important events affecting the Group occurred after the Reporting Period and up to the date of this interim report.

INTERIM DIVIDENDS

The Board does not recommend the payment of interim dividends for the six months ended June 30, 2023 to the Shareholders (June 30, 2022: nil).

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries purchased, sold or redeemed any listed securities of the Company for the six months ended June 30, 2023.

COMPLETION OF H SHARE FULL CIRCULATION

During the Reporting Period, the Company received approvals for the full circulation of its H Shares from the CSRC and for the listing of and dealing in 27,482,883 H Shares from the Stock Exchange. On July 3, 2023, the Company completed the conversion of 27,482,883 Unlisted Shares into H Shares. For further details, please refer to the Company's announcements dated March 28, 2023, May 11, 2023 and July 3, 2023.

報告期後事項

除本中期報告所披露者外，於報告期後及直至本中期報告日期止概無發生影響本集團的重大事件。

中期股息

董事會並不建議向股東派付截至2023年6月30日止六個月的中期股息(2022年6月30日：無)。

購買、出售或贖回本公司的上市證券

截至2023年6月30日止六個月，本公司或其任何附屬公司均未購買、出售或贖回本公司的任何上市證券。

完成H股全流通

於報告期內，本公司已接獲中國證監會就其H股全流通及聯交所就27,482,883股H股上市及買賣授出的批准。於2023年7月3日，本公司已將27,482,883股未上市股份轉換為H股。有關進一步詳情，請參閱本公司日期為2023年3月28日、2023年5月11日及2023年7月3日的公告。

OTHER INFORMATION

其他資料

CHANGE IN CONSTITUTIONAL DOCUMENTS

On May 23, 2023, the Board resolved to approve the amendments to the articles of association of the Company. Such amendments were approved by the Shareholders at the annual general meeting of the Company held on June 27, 2023. For further details, please refer to the Company's announcement and circular dated May 23, 2023 and May 25, 2023, respectively.

Save as disclosed above, there was no significant change to the constitutional documents of the Company for the six months ended June 30, 2023.

SHARE INCENTIVES SCHEME

Incentives granted prior to the Listing

Airdoc Universe, Suqian Airdoc and Suqian Zhongyou were established in the PRC as our employee incentive platforms, and respectively held approximately 5.15%, 4.02% and 2.24% of the total issued Shares of the Company as of the date of this interim report. For further details of the employee incentive platforms, please refer to the Prospectus.

章程文件的變動

於2023年5月23日，董事會議決批准修訂本公司組織章程細則。該等修訂已於本公司於2023年6月27日舉行的股東週年大會獲股東批准。有關進一步詳情，請參閱本公司日期分別為2023年5月23日及2023年5月25日的公告及通函。

除上述披露外，截至2023年6月30日止六個月，本公司章程文件並無重大變動。

股權激勵計劃

於上市前授予的激勵

鬱金香宇宙、宿遷鷹瞳及宿遷眾佑均為在中國成立的本公司員工激勵平台，且截至本中期報告日期，彼等分別於本公司已發行股份總數中擁有約5.15%、4.02%及2.24%的權益。有關員工激勵平台的更多詳情，請參閱招股章程。

OTHER INFORMATION 其他資料

2022 Equity Incentive Scheme

On January 13, 2023, the Board resolved to adopt the 2022 Equity Incentive Scheme (the “**Scheme**”), which was subsequently approved by the Shareholders at the extraordinary general meeting of the Company held on March 30, 2023. The Scheme shall be valid and effective for a period of five (5) years commencing from March 30, 2023. The maximum number of Incentive Shares grantable under the Scheme shall not exceed 6,214,080 H Shares, which shall be satisfied by the H Shares to be purchased in the open market by trustee.

Grant under the scheme

On January 13, 2023, the Board resolved to grant a total of 3,107,040 Incentive Shares to Mr. Zhang pursuant to the terms of the Scheme, conditional upon the approval of the Scheme by the Shareholders. The Incentives were granted to Mr. Zhang for nil consideration. Pursuant to the grant agreement, twenty-five percent (25%) of the Incentive Shares granted to Mr. Zhang shall vest on December 31, 2023 and the rest of the Incentive Shares granted to Mr. Zhang will equally vest yearly in three years thereafter. The closing price of the H Share immediately before the date of grant was HK\$12.2 per H Share. The fair value of the Incentives granted to Mr. Zhang at the date of grant was HK\$41.7 million, calculated based on the closing price of the H Shares of HK\$13.42 per H Share as stated in the Stock Exchange’s daily quotation sheet on the date of grant multiplied by the number of Incentive Shares granted. As of the date of this interim report, the Company did not purchase any H Shares for the purpose of satisfying the Incentives granted. As of the same date, none of the Incentives granted were canceled or lapsed.

2022年股權激勵計劃

於2023年1月13日，董事會議決採納2022年股權激勵計劃（「該計劃」），該計劃其後經股東於本公司於2023年3月30日舉行的股東特別大會上批准。該計劃自2023年3月30日開始起計五(5)年期限內生效及有效。根據該計劃可授予的激勵股份的最高數目不得超過6,214,080股H股，由受託人從公開市場購買的H股支付。

根據計劃授予

於2023年1月13日，董事會議決根據該計劃的條款向張先生授予合共3,107,040股激勵股份，須待股東批准該計劃後，方可作實。激勵無償授予張先生。根據授予協議，授予張先生的激勵股份的百分之二十五(25%)將於2023年12月31日歸屬，而授予張先生的餘下激勵股份將於此後三年內每年平均歸屬。H股於緊接授予日期前的收市價為每股H股12.2港元。於授予日期，授予張先生的激勵的公允價值為41.7百萬港元，乃基於H股於授予日期載於聯交所每日報價表的收市價每股H股13.42港元乘以已授予的激勵股份數目計算。截至本中期報告日期，本公司並無為支付已授予的激勵而購買任何H股。截至同日，概無已授出激勵註銷或失效。

OTHER INFORMATION

其他資料

Save as disclosed above, the Company did not make any other grants under the Scheme as of the date of this interim report.

As the Incentives were granted to Mr. Zhang pursuant to his service contract with the Group and form part of his remuneration package thereunder, the grant of Incentives to Mr. Zhang is exempt from the reporting, announcement and independent Shareholders' approval requirements under Rules 14A.73(6) and 14A.95 of the Listing Rules.

As of the date of this interim report, save as disclosed above, the Company did not have any other share incentive scheme or make any grant that is subject to the disclosure requirements under Chapter 17 of the Listing Rules.

MATERIAL LITIGATION

The Company was not involved in any material litigation or arbitration for the six months ended June 30, 2023. The Directors are also not aware of any material litigations or claims that are pending or threatened against the Group during the six months ended June 30, 2023.

除上文所披露者外，截至本中期報告日期，本公司並無根據該計劃作出任何其他授予。

由於激勵乃根據張先生與本集團簽訂的服務合約而授予，並構成其薪酬待遇的一部分，因此向張先生授予激勵豁免遵守上市規則第14A.73(6)及14A.95條的申報、公告及獨立股東批准規定。

截至本中期報告日期，除上文所披露者外，本公司並無須依據上市規則第十七章披露規定的股權激勵計劃或作出任何授予。

重大訴訟

截至2023年6月30日止六個月，本公司無涉及任何重大訴訟或仲裁事項。於截至2023年6月30日止六個月內，就董事所知，亦無任何尚未了結或本集團可能面臨的重大訴訟或索賠。

OTHER INFORMATION 其他資料

CHANGES IN THE INFORMATION OF THE DIRECTORS

董事之資料變動

Pursuant to Rule 13.51B of the Listing Rules, the changes in the information of the Directors during the Reporting Period and up to the date of this interim report, are set out below:

根據上市規則第13.51B條，董事之資料於報告期內及直至本中期報告日期之變動如下：

1. On January 13, 2023, Mr. GAO Fei (高斐) resigned as an executive Director due to his desire to devote more time to his family and other work commitment;
1. 高斐先生於2023年1月13日由於擬將更多時間關注家庭及其他工作，已辭任執行董事；
2. On January 13, 2023, Ms. WANG Mi (王謐) resigned as a non-executive Director due to other work engagement;
2. 王謐女士於2023年1月13日由於其他工作安排已辭任非執行董事；
3. Ms. WANG Lin (王林) has been appointed as an executive Director with effect from March 30, 2023; and
3. 王林女士獲委任為執行董事，於2023年3月30日起生效；及
4. Ms. ZHU Tingyao (朱艇遙) (“Ms. Zhu”) has been appointed as a non-executive Director with effect from March 30, 2023. On July 27, 2023, Ms. Zhu resigned as a non-executive Director due to other work engagement.
4. 朱艇遙女士(「朱女士」)獲委任為非執行董事，於2023年3月30日起生效。於2023年7月27日，朱女士由於其他工作安排已辭任非執行董事。

Save as disclosed above, the Directors hereby confirm that no information is required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

除上述所披露者外，董事謹此確認概無資料須根據上市規則第13.51B(1)條予以披露。

OTHER INFORMATION

其他資料

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

None of the Directors or any of their respective associates were granted by the Company or its subsidiaries any right to acquire shares in, or debentures of, the Company or its subsidiary, or had exercised any such right during the six months ended June 30, 2023.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

The Company does not have any other disclosure obligations pursuant to Rules 13.20, 13.21 and 13.22 of the Listing Rules.

REVIEW OF FINANCIAL STATEMENTS

The Audit Committee comprises three independent non-executive Directors, namely Mr. NG Kong Ping Albert, Dr. HUANG Yanlin and Dr. WU Yangfeng. Mr. NG Kong Ping Albert, being the chairman of the committee, is appropriately qualified as required under Rules 3.10(2) and 3.21 of the Listing Rules. The primary duties of the Audit Committee are to assist the Board by providing an independent view of the effectiveness of the financial reporting process, internal control and risk management systems of the Company and overseeing the audit process. The Audit Committee has reviewed the interim results of the Group for the six months ended June 30, 2023 and has recommended for the Board's approval thereof. The Audit Committee has reviewed together with the management the accounting principles and policies adopted by the Company and discussed internal control and financial reporting matters (including the review of the unaudited interim results and interim report of the Group for the six months ended June 30, 2023) of the Group.

董事收購股份或債權證之權利

於截至2023年6月30日止六個月期間，本公司或其附屬公司均未授予董事或任何彼等各自的聯繫人收購本公司或其附屬公司股份或債權證的權利，或行使該等權利。

根據上市規則的持續披露責任

本公司並無根據上市規則第13.20條、13.21條及13.22條項下的任何其他披露責任。

審閱財務報表

審核委員會由三名獨立非執行董事組成，即吳港平先生、黃彥林博士及武陽豐博士。吳港平先生為委員會主席，具備上市規則第3.10(2)條及3.21條規定的合適資格。審核委員會的主要職責是協助董事會就本公司財務報告流程、內部控制及風險管理系統的有效性提供獨立意見，並監督審核程序。審核委員會已審閱本集團截至2023年6月30日止六個月的中期業績，並建議董事會批准。審核委員會已與管理層一同審閱本公司採納的會計原則及政策並討論本集團的內部控制及財務申報事宜（包括審閱本集團截至2023年6月30日止六個月的未經審核中期業績及中期報告）。

OTHER INFORMATION 其他資料

APPRECIATION

We wish to express our sincere gratitude to our shareholders and business partners for their continued support, and to our employees for their dedication and hard work.

By order of the Board
Beijing Airdoc Technology Co., Ltd.
Mr. ZHANG Dalei
Chairman of the Board

Hong Kong, August 25, 2023

致謝

我們謹此就股東和業務夥伴的持續支持以及我們僱員的恪盡職守及辛勤工作向彼等致以衷心感謝。

承董事會命
北京鷹瞳科技發展股份有限公司
董事會主席
張大磊先生

香港 · 2023年8月25日

INDEPENDENT REVIEW REPORT

獨立審閱報告



Ernst & Young
27/F, One Taikoo Place
979 King's Road
Quarry Bay, Hong Kong

安永會計師事務所
香港鰂魚涌
英皇道979號
太古坊一座27樓

Tel 電話: +852 2846 9888
Fax 傳真: +852 2868 4432
ey.com

Independent review report

To the board of directors of Beijing Airdoc Technology Co., Ltd.

(Incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 56 to 93, which comprises the condensed consolidated statement of financial position of Beijing Airdoc Technology Co., Ltd. (the “**Company**”) and its subsidiaries (the “**Group**”) as at 30 June 2023 and the related condensed consolidated statements of profit or loss, comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* (“**IAS 34**”) issued by the International Accounting Standards Board (“**IASB**”). The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

獨立審閱報告

致北京鷹瞳科技發展股份有限公司董事會

(於中華人民共和國註冊成立的有限公司)

緒言

我們已審閱列載於56至93頁的中期財務資料，包括北京鷹瞳科技發展股份有限公司（「**貴公司**」）及其附屬公司（「**貴集團**」）截至2023年6月30日的簡明綜合財務狀況表以及截至該日止六個月期間的相關簡明綜合損益表、簡明綜合收益表、簡明綜合權益變動表及簡明綜合現金流量表以及解釋附註。《香港聯合交易所有限公司證券上市規則》規定，編製中期財務資料的報告須遵守其相關條文及國際會計準則理事會（「**國際會計準則理事會**」）頒佈的《國際會計準則》第34號「中期財務報告」（「**國際會計準則第34號**」）。貴公司董事負責根據國際會計準則第34號編製並呈列本中期財務資料。我們的責任是根據我們的審閱對中期財務資料作出結論，並按照協定的委聘條款僅向整體董事會作出報告，除此之外，我們的報告不可用作其他用途。我們不就本報告內容向任何其他人士負責或承擔責任。

INDEPENDENT REVIEW REPORT 獨立審閱報告

SCOPE OF REVIEW

We conducted our review in accordance with Hong Kong Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Hong Kong Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young
Certified Public Accountants
Hong Kong

25 August 2023

審閱範圍

我們已根據香港會計師公會（「香港會計師公會」）發出的《香港審閱委聘準則》第2410號「實體的獨立核數師對中期財務資料的審閱」進行審閱。中期財務資料的審閱包括對主要負責財務及會計事務的人員作出詢問，並實施分析及其他審閱程序。審閱的範圍遠小於根據《香港審計準則》進行的審核，故無法保證我們會注意到所有可通過審核發現的重大事項。據此，我們不會發表審核意見。

結論

根據我們的審閱，我們並無發現任何事項，令我們相信，中期財務資料於所有重大方面未有按照國際會計準則第34號編製。

安永會計師事務所
執業會計師
香港

2023年8月25日

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS

中期簡明綜合損益表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

			For the six months ended 30 June 截至6月30日止六個月	
			2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
		Notes 附註		
REVENUE	收入	4	82,502	37,407
Cost of sales	銷售成本		(31,138)	(15,336)
Gross profit	毛利		51,364	22,071
Other income and gains	其他收入及收益	5	49,786	28,593
Selling and distribution expenses	銷售及分銷開支		(44,292)	(48,857)
Administrative expenses	行政開支		(40,595)	(31,726)
Research and development expenses	研發開支		(56,517)	(69,573)
Finance costs	財務成本	6	(275)	(192)
LOSS BEFORE TAX	除稅前虧損	7	(40,529)	(99,684)
Income tax expense	所得稅開支	8	(488)	—
LOSS FOR THE PERIOD	期內虧損		(41,017)	(99,684)
Attributable to:	以下人士應佔：			
Owners of the parent	母公司擁有人		(36,970)	(99,684)
Non-controlling interests	非控股權益		(4,047)	—
			(41,017)	(99,684)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通權益持有 人應佔的每股虧損	10		
Basic and diluted (expressed in RMB)	基本及攤薄 (以人民幣列示)		(0.36)	(0.98)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

中期簡明綜合收益表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
LOSS FOR THE PERIOD	期內虧損	(41,017)	(99,684)
OTHER COMPREHENSIVE LOSS	其他綜合虧損		
Other comprehensive loss that may be reclassified to profit or loss in subsequent periods:	其後可重新分類至損益的其他綜合虧損：		
Exchange differences on translation of the financial statements of a subsidiary attributable to owners of the parent	換算一家附屬公司的財務報表時所產生的母公司擁有人應佔匯兌差額	(192)	(76)
Exchange differences on translation of the financial statements of a subsidiary attributable to non-controlling interests	換算一家附屬公司的財務報表時所產生的非控股權益應佔匯兌差額	(76)	—
Other comprehensive loss that will not be reclassified to profit or loss in subsequent periods:	其後不會重新分類至損益的其他綜合虧損：		
Equity investments designated at fair value through other comprehensive income	指定為以公允價值計量且其變動計入其他綜合收益的權益投資	(932)	—
OTHER COMPREHENSIVE LOSS FOR THE PERIOD, NET OF TAX	期內其他綜合虧損，經扣除稅項：	(1,200)	(76)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	期內綜合虧損總額	(42,217)	(99,760)
Attributable to:	以下人士應佔：		
Owners of the parent	母公司擁有人	(38,094)	(99,760)
Non-controlling interests	非控股權益	(4,123)	—
		(42,217)	(99,760)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2023 於2023年6月30日

			30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
		Notes 附註		
NON-CURRENT ASSETS				
	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	16,771	24,158
Right-of-use assets	使用權資產		13,039	8,918
Goodwill	商譽	20	128,338	970
Other intangible assets	其他無形資產		96,917	5,858
Other financial assets	其他金融資產	14	105,420	20,319
Other non-current assets	其他非流動資產		4,183	3,914
Total non-current assets	非流動資產總值		<u>364,668</u>	<u>64,137</u>
CURRENT ASSETS				
	流動資產			
Inventories	存貨		54,572	29,571
Trade receivables	應收賬款	12	80,769	63,877
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	13	27,475	19,386
Other financial assets	其他金融資產	14	276,497	144,734
Time deposits over three months	三個月以上的定期存款	15	93,148	—
Restricted bank deposits	受限制銀行存款	15	—	150,000
Cash and cash equivalents	現金及現金等價物	15	876,360	1,268,250
Total current assets	流動資產總值		<u>1,408,821</u>	<u>1,675,818</u>
CURRENT LIABILITIES				
	流動負債			
Trade payables	應付賬款	16	22,868	6,625
Other payables and accruals	其他應付款項及應計費用	17	31,410	35,404
Contract liabilities	合約負債		26,504	18,197
Lease liabilities	租賃負債		7,994	4,085
Tax payable	應付稅項		1,486	354
Total current liabilities	流動負債總額		<u>90,262</u>	<u>64,665</u>
NET CURRENT ASSETS	流動資產淨值		<u>1,318,559</u>	<u>1,611,153</u>
TOTAL ASSETS LESS CURRENT LIABILITIES	資產總值減流動負債		<u>1,683,227</u>	<u>1,675,290</u>

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2023 於2023年6月30日

			30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
	Notes 附註			
NON-CURRENT LIABILITIES	非流動負債			
Deferred tax liabilities	遞延稅項負債		13,914	—
Lease liabilities	租賃負債		4,264	3,928
Total non-current liabilities	非流動負債總額		<u>18,178</u>	<u>3,928</u>
Net assets	淨資產		<u>1,665,049</u>	<u>1,671,362</u>
EQUITY	權益			
Equity attributable to owners of the parent	母公司擁有人應佔權益			
Share capital	股本	18	103,568	103,568
Reserves	儲備		<u>1,535,610</u>	<u>1,562,557</u>
Non-controlling interests	非控股權益		<u>1,639,178</u>	<u>1,666,125</u>
Total equity	權益總額		<u>1,665,049</u>	<u>1,671,362</u>

Zhang Dalei

張大磊

Director

董事

Chen Yuzhong

陳羽中

Director

董事

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

中期簡明綜合權益變動表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

		Attributable to owners of the parent 母公司擁有人應佔								
		Share capital	Share premium	Fair value reserve of financial assets at fair value through other comprehensive income 以公允價值計量且其變動計入其他綜合收益的金融資產的	Other reserve	Exchange fluctuation reserve	Accumulated losses	Total	Non-controlling interests	Total equity
		股本 RMB'000 人民幣千元	股份溢價 RMB'000 人民幣千元	公允價值儲備 RMB'000 人民幣千元	其他儲備 RMB'000 人民幣千元	匯兌變動儲備 RMB'000 人民幣千元	累計虧損 RMB'000 人民幣千元	合計 RMB'000 人民幣千元	非控股權益 RMB'000 人民幣千元	權益總額 RMB'000 人民幣千元
At 1 January 2023 (audited)	於2023年1月1日(經審核)	103,568	1,827,965	1,274	78,206	673	(345,561)	1,666,125	5,237	1,671,362
Loss for the period	期內虧損	—	—	—	—	—	(36,970)	(36,970)	(4,047)	(41,017)
Other comprehensive loss for the period:	期內其他綜合虧損:									
Change in fair value of equity investments at fair value through other comprehensive income, net of tax	以公允價值計量且其變動計入其他綜合收益的權益投資的公允價值變動(扣除稅項)	—	—	(932)	—	—	—	(932)	—	(932)
Exchange differences on translation of foreign operations	換算境外營運的匯兌差額	—	—	—	—	(192)	—	(192)	(76)	(268)
Total comprehensive loss for the period	期內綜合虧損總額	—	—	(932)	—	(192)	(36,970)	(38,094)	(4,123)	(42,217)
Acquisition of subsidiaries	收購附屬公司	—	—	—	—	—	—	—	23,412	23,412
Contributions from a non-controlling shareholder	非控股股東出資	—	—	—	—	—	—	—	1,345	1,345
Equity-settled share-based transactions	以權益結算的股份支付交易	—	—	—	11,147	—	—	11,147	—	11,147
At 30 June 2023 (unaudited)	於2023年6月30日(未經審核)	103,568	1,827,965	342	89,353	481	(382,531)	1,639,178	25,871	1,665,049

		Attributable to owners of the parent 母公司擁有人應佔								
		Share capital	Share premium	Fair value reserve of financial assets at fair value through other comprehensive income 以公允價值計量且其變動計入其他綜合收益的金融資產的	Other reserve	Exchange fluctuation reserve	Accumulated losses	Total	Non-controlling interests	Total equity
		股本 RMB'000 人民幣千元	股份溢價 RMB'000 人民幣千元	公允價值儲備 RMB'000 人民幣千元	其他儲備 RMB'000 人民幣千元	匯兌變動儲備 RMB'000 人民幣千元	累計虧損 RMB'000 人民幣千元	合計 RMB'000 人民幣千元	非控股權益 RMB'000 人民幣千元	權益總額 RMB'000 人民幣千元
At 1 January 2022 (audited)	於2022年1月1日(經審核)	101,248	1,827,965	1,607	54,394	330	(165,558)	1,819,986	—	1,819,986
Loss for the period	期內虧損	—	—	—	—	—	(99,684)	(99,684)	—	(99,684)
Other comprehensive loss for the period:	期內其他綜合虧損:									
Exchange differences on translation of foreign operations	換算境外營運的匯兌差額	—	—	—	—	(76)	—	(76)	—	(76)
Total comprehensive loss for the period	期內綜合虧損總額	—	—	—	—	(76)	(99,684)	(99,760)	—	(99,760)
Equity-settled share-based transactions	以權益結算的股份支付交易	—	—	—	17,248	—	—	17,248	—	17,248
Contributions from shareholders	股東出資	—	—	—	2,320	—	—	2,320	—	2,320
At 30 June 2022 (unaudited)	於2022年6月30日(未經審核)	101,248	1,827,965	1,607	73,962	254	(265,242)	1,739,794	—	1,739,794

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

For the six months ended 30 June
截至6月30日止六個月

			2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
	Notes 附註			
CASH FLOWS FROM OPERATING ACTIVITIES	經營活動所得現金 流量			
Loss before tax	稅前虧損		(40,529)	(99,684)
Adjustments for:	就以下各項進行 調整：			
Finance costs	財務成本	6	275	192
Interest Income	利息收入	5	(8,976)	(2,156)
Depreciation of property, plant and equipment	物業、廠房及設備 折舊	7	8,412	8,032
Amortisation of other intangible assets	其他無形資產攤銷	7	941	—
Depreciation of right-of-use assets	使用權資產折舊	7	4,192	2,865
Provision for impairment of trade receivables	應收賬款減值撥備	12	2,840	707
Provision for impairment of other receivables	其他應收款項減值 撥備	13	98	11
Foreign exchange differences	匯兌差額	5	(7,805)	(40,848)
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且 其變動計入當期 損益的金融資產 的公允價值收益	5	(9,841)	(7,549)
Investment (income)/loss from financial assets	金融資產投資 (收入)/虧損	5	(22,588)	22,188
Equity-settled share-based transactions	以權益結算的股份 支付交易	7	11,147	17,248
			(61,834)	(98,994)
Increase in inventories	存貨增加		(14,041)	(3,506)
Increase in trade receivables	應收賬款增加		(16,764)	(10,378)
(Increase)/decrease in prepayments, other receivables and other assets	預付款項、其他應收 款項及其他資產 (增加)/減少		(7,549)	3,906
Increase/(decrease) in trade payables	應付賬款增加/ (減少)		3,945	(2,466)
Decrease in other payables and accruals	其他應付款項及應計 費用減少		(10,964)	(8,427)
Increase/(decrease) in contract liabilities	合約負債增加/ (減少)		8,307	(1,731)
Cash used in operations	經營所用現金		(98,900)	(121,596)
Interest received	已收利息		3,001	2,156
Net cash flows used in operating activities	經營活動所用現金 流量淨額		(95,899)	(119,440)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

For the six months ended 30 June
截至6月30日止六個月

	Notes 附註	2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Net cash flows used in operating activities	經營活動所用現金 流量淨額	(95,899)	(119,440)
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金 流量		
Proceeds from disposal of property, plant and equipment	出售物業、廠房及 設備所得款項	11 1,136	605
Proceeds from disposal of other financial assets	出售其他金融資產 所得款項	1,455,963	1,072,778
Proceeds from disposal of time deposits	出售定期存款所得 款項	15 153,525	—
Purchases of items of property, plant and equipment	購買物業、廠房及 設備項目	11 (2,161)	(7,239)
Purchases of financial assets	購買金融資產	(1,641,216)	(1,161,876)
Purchase of time deposits	購買定期存款	15 (90,698)	(150,000)
Acquisition of subsidiaries	收購附屬公司	20 (176,810)	—
Prepayment for purchase of other long-term assets	購買其他長期資產的 預付款項	(269)	(4,500)
Net cash flows used in investing activities	投資活動所用現金 流量淨額	(300,530)	(250,232)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金 流量		
Contributions from shareholders	股東出資	—	2,320
Contributions from a non-controlling shareholder	非控股股東出資	1,345	—
Principal portion of lease payments	租賃付款的本金部分	(4,342)	(2,834)
Net cash flows used in financing activities	融資活動所用現金 流量淨額	(2,997)	(514)
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等價物 減少淨額	(399,426)	(370,186)
Cash and cash equivalents at beginning of period	期初現金及現金等 價物	1,268,250	1,784,648
Effect of foreign exchange rate changes, net	外匯匯率變動的 影響·淨額	7,536	6,819
CASH AND CASH EQUIVALENTS AT END OF PERIOD	期末的現金及現金等 價物	876,360	1,421,281

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2023 截至2023年6月30日止六個月

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS			
	現金及現金等價物 結餘分析		
Cash and bank balances	現金及銀行結餘	853,310	1,421,281
Non-pledged time deposits with original maturity of less than three months when acquired	購入時原到期日少於三個月的無抵押定期存款	23,050	—
Cash and cash equivalents as stated in the interim condensed consolidated statement of financial position	呈列於中期簡明綜合財務狀況表的現金及現金等價物	876,360	1,421,281
Cash and cash equivalents as stated in the interim condensed consolidated statement of cash flows	呈列於中期簡明綜合現金流量表的現金及現金等價物	876,360	1,421,281

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2023 has been prepared in accordance with IAS 34 *Interim Financial Reporting*. The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements for the year ended 31 December 2022.

Beijing Airdoc Technology Co., Ltd. (the “**Company**”) was established as a limited liability company in the People's Republic of China (the “**PRC**”) on 9 September 2015. The Company was converted from a limited liability company into a joint stock limited liability company on 28 December 2020. The Company was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) on 5 November 2021.

The Company and its subsidiaries (together, the “**Group**”) are primarily focusing on providing AI-empowered retina-based early detection, diagnosis and health risk assessment solutions.

1. 編製基準

截至2023年6月30日止六個月的中期簡明綜合財務資料已根據《國際會計準則》第34號「中期財務報告」編製。中期簡明綜合財務資料不包括年度財務報表規定的所有資料及披露，應與本集團截至2022年12月31日止年度的年度綜合財務報表一併閱讀。

北京鷹瞳科技發展股份有限公司（「**本公司**」）於2015年9月9日在中華人民共和國（「**中國**」）成立為有限責任公司。本公司於2020年12月28日由有限責任公司改制為股份有限公司。本公司於2021年11月5日在香港聯合交易所有限公司（「**聯交所**」）主板上市。

本公司及其附屬公司（統稱「**本集團**」）主要專注於提供人工智能視網膜影像識別的早期檢測、診斷及健康風險評估解決方案。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2022, except for the adoption of the following revised International Financial Reporting Standards ("IFRSs") for the first time for the current period's financial information.

Amendments to IAS 1 *Disclosure of Accounting Policies* and IFRS Practice Statement 2

Amendments to IAS 8 *Definition of Accounting Estimates*

Amendments to IAS 12 *Deferred Tax related to Assets and Liabilities arising from a Single transaction*

Amendments to IAS 12 *International Tax Reform – Pillar Two Model Rules*

2. 會計政策變動及披露

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至2022年12月31日止年度的年度綜合財務報表所應用者一致，惟於本期間財務資料首次採用以下經修訂《國際財務報告準則》(「《國際財務報告準則》」)除外。

《國際會計準則》第1號及《國際財務報告準則實務公告》第2號(修訂本) 會計政策的披露

《國際會計準則》第8號(修訂本) 會計估計的定義

《國際會計準則》第12號(修訂本) 產生自單一交易的資產及負債相關的遞延稅項

《國際會計準則》第12號(修訂本) 國際稅務改革 – 支柱二立法模版

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

The nature and impact of the revised IFRSs that are applicable to the Group are described below:

- (a) Amendments to IAS 1 require entities to disclose their material accounting policy information rather than their significant accounting policies. Accounting policy information is material if, when considered together with other information included in an entity's financial statements, it can reasonably be expected to influence decisions that the primary users of general purpose financial statements make on the basis of those financial statements. Amendments to IFRS Practice Statement 2 provide non-mandatory guidance on how to apply the concept of materiality to accounting policy disclosures. The Group has applied the amendments since 1 January 2023. The amendments did not have any impact on the Group's interim condensed consolidated financial information and are not expected to have a significant impact on the accounting policy disclosures in the Group's annual consolidated financial statements.

2. 會計政策變動及披露(續)

適用於本集團經修訂《國際財務報告準則》的性質及影響如下所述：

- (a) 《國際會計準則》第1號(修訂本)要求實體披露重大會計政策資料，而非主要會計政策。倘會計政策資料與實體財務報表所載其他資料一併考慮時，可能合理預期影響一般用途財務報表的主要使用者基於該等財務報表作出的決定，則該等資料屬重大。《國際財務報告準則實務報告》第2號(修訂本)為如何應用會計政策披露的重要性概念提供非強制性指引。本集團自2023年1月1日起應用該等修訂本。該等修訂本並未對本集團中期簡明綜合財務資料產生任何影響，並預計不會對本集團年度綜合財務報表的會計政策披露產生重大影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

- (b) Amendments to IAS 8 clarify the distinction between changes in accounting estimates and changes in accounting policies. Accounting estimates are defined as monetary amounts in financial statements that are subject to measurement uncertainty. The amendments also clarify how entities use measurement techniques and inputs to develop accounting estimates. The Group has applied the amendments to changes in accounting policies and changes in accounting estimates that occur on or after 1 January 2023. Since the Group's policy of determining accounting estimates aligns with the amendments, the amendments did not have any impact on the financial position or performance of the Group.
- (c) Amendments to IAS 12 *Deferred Tax related to Assets and Liabilities arising from a Single Transaction* narrow the scope of the initial recognition exception in IAS 12 so that it no longer applies to transactions that give rise to equal taxable and deductible temporary differences, such as leases and decommissioning obligations. Therefore, entities are required to recognise a deferred tax asset (provided that sufficient taxable profit is available) and a deferred tax liability for temporary differences arising from these transactions. The Group has applied the amendments on temporary differences related to leases as at 1 January 2022, with any cumulative effect recognised as an adjustment to the balance of retained profits or other component of equity as appropriate at that date. In addition, the Group has applied the amendments prospectively to transactions other than leases that occurred on or after 1 January 2022, if any.

2. 會計政策變動及披露(續)

- (b) 《國際會計準則》第8號(修訂本)澄清會計估計變動與會計政策變動之間的區別。會計估計被定義為財務報表中存在計量不確定性的貨幣金額。該修訂本亦澄清實體如何使用計量技術及輸入值作出會計估計。本集團已對於2023年1月1日或之後發生的會計政策變動及會計估計變動應用該修訂。由於本集團釐定會計估計的政策與該修訂本一致，該修訂本並未對本集團財務狀況或業績產生任何影響。
- (c) 《國際會計準則》第12號(修訂本)「與單一交易產生的資產及負債相關的遞延稅項」收窄《國際會計準則》第12號初始確認豁免的範圍，以致不再適用於會產生等額應課稅及可扣稅暫時性差額的交易，例如租賃及停用責任。因此，實體須就該等交易產生的暫時性差額確認遞延稅項資產(惟須存有充足應課稅溢利)及遞延稅項負債。本集團已對截至2022年1月1日的租賃有關的暫時性差額應用該修訂本，任何累計影響確認為當日對保留溢利或權益其他組成部分(倘適用)結餘的調整。此外，本集團已將該修訂本前瞻性地應用於2022年1月1日或之後發生的除租賃以外的交易(如有)。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

(c) (continued)

Prior to the initial application of these amendments, the Group applied the initial recognition exception and did not recognise a deferred tax asset and a deferred tax liability for temporary differences for transactions related to leases. Upon initial application of these amendments, the Group recognised (i) a deferred tax asset for all deductible temporary differences associated with lease liabilities (provided that sufficient taxable profit is available) and (ii) a deferred tax liability for all taxable temporary differences associated with right-of-use assets as at 1 January 2022.

The adoption of amendments to IAS 12 did not have any impact on the interim condensed consolidated statement of profit or loss.

The adoption of amendments to IAS 12 did not have any impact on the basic and diluted earnings per share attributable to ordinary equity holders of the parent, other comprehensive income and the interim condensed consolidated statements of cash flows for the six months ended 30 June 2023 and 2022.

2. 會計政策變動及披露 (續)

(c) (續)

於首次應用該等修訂之前，本集團已應用初始確認豁免的範圍，且並無就租賃相關交易的暫時性差額確認遞延稅項資產及遞延稅項負債。於首次應用該等修訂時，本集團確認(i)與租賃負債相關的所有可扣除暫時性差額的遞延稅項資產(倘有足夠的應課稅利潤)及(ii)截至2022年1月1日與使用權資產相關的所有應課稅暫時性差額的遞延稅項負債。

採納《國際會計準則》第12號(修訂本)並未對中期簡明綜合損益表產生任何影響。

採納《國際會計準則》第12號(修訂本)並未對截至2023年及2022年6月30日止六個月母公司普通權益持有人應佔基本及攤薄每股收益、其他綜合收益及中期簡明綜合現金流量表產生任何影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (continued)

(d) Amendments to IAS 12 *International Tax Reform – Pillar Two Model Rules* introduce a mandatory temporary exception from the recognition and disclosure of deferred taxes arising from the implementation of the Pillar Two model rules published by the Organisation for Economic Co-operation and Development. The amendments also introduce disclosure requirements for the affected entities to help users of the financial statements better understand the entities' exposure to Pillar Two income taxes, including the disclosure of current tax related to Pillar Two income taxes separately in the periods when Pillar Two legislation is effective and the disclosure of known or reasonably estimable information of their exposure to Pillar Two income taxes in periods in which the legislation is enacted or substantively enacted but not yet in effect. Entities are required to disclose the information relating to their exposure to Pillar Two income taxes in annual periods beginning on or after 1 January 2023, but are not required to disclose such information for any interim periods ending on or before 31 December 2023. Since the Group did not fall within the scope of the Pillar Two model rules, the amendments did not have any impact to the Group.

3. OPERATING SEGMENT INFORMATION

IFRS 8 *Operating Segments* requires identification and disclosure of operating segment information based on internal financial reports that are regularly reviewed by the Group's chief operating decision maker for the purpose of resource allocation and performance assessment. On this basis, the Group has determined that it only has one operating segment during the six months ended 30 June 2023.

2. 會計政策變動及披露(續)

(d) 《國際會計準則》第12號(修訂本)「國際稅務改革 – 支柱二立法模版」，引入因實施經濟合作及發展組織公佈的支柱二立法模版而產生的遞延稅項確認及披露的強制性暫時豁免。該修訂本還為受影響的實體引入了披露要求，以幫助財務報表使用者更好地了解實體面臨的支柱二所得稅風險，包括在支柱二立法生效期間單獨披露與支柱二所得稅相關的當期稅項，以及在立法已頒佈或實質上已頒佈但尚未生效期間披露其面臨的支柱二所得稅風險的已知或可合理估計的信息。實體必須在2023年1月1日或之後開始的年度期間披露與支柱二所得稅風險有關的信息，但在2023年12月31日或之前結束的任何中期期間無需披露有關信息。由於本集團不屬於支柱二立法模版的範疇，因此該修訂本並未對本集團產生任何影響。

3. 經營分部資料

《國際財務報告準則》第8號「經營分部」要求根據內部財務報告識別及披露經營分部資料，該等報告由本集團的主要經營決策者為資源分配及業績評估目的定期審查。在此基礎上，本集團已確定截至2023年6月30日止六個月其僅有一個經營分部。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

4. REVENUE

An analysis of revenue is as follows:

4. 收入

收入分析如下：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Revenue from contracts with customers	來自客戶合約的收入	82,502	37,407
Disaggregated revenue information for revenue from contracts with customers	來自客戶合約收入的分類收入資料		
<i>Disaggregated by customer type</i>	<i>按客戶類型分類</i>		
Integrated solution of AI-based software and hardware:	人工智能軟件及硬件一體化解決方案：		
Medical institutions (Airdoc Medical)	醫療機構（鷹瞳醫療）	29,845	12,577
Consumer healthcare environments (Airdoc Health)	大健康場景（鷹瞳健康）	21,693	17,223
Eye health management settings (Airdoc Eye Health)	眼健康管理場景（鷹瞳眼健康）	30,964	7,607
Total revenue from contracts with customers	來自客戶合約的收入總額	82,502	37,407
<i>Disaggregated by geographical market</i>	<i>按地區市場分類</i>		
Mainland China	中國內地	78,566	36,926
Other countries/regions	其他國家／地區	3,936	481
Total revenue from contracts with customers	來自客戶合約的收入總額	82,502	37,407
<i>Disaggregated by timing of revenue recognition</i>	<i>按收入確認的時間分類</i>		
Goods or services transferred at a point in time	於某一時點轉讓的貨品或服務	69,000	17,185
Services transferred over time	隨時間推移轉讓的服務	13,502	20,222
Total revenue from contracts with customers	來自客戶合約的收入總額	82,502	37,407

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

5. OTHER INCOME AND GAINS

An analysis of other income and gains is as follows:

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Other income and gains	其他收入及收益		
Investment income/(loss) from financial assets	金融資產投資收入/(虧損)	22,588	(22,188)
Fair value gains on financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產的公允價值收益	9,841	7,549
Net foreign exchange gain	外匯收益淨額	7,805	40,848
Interest income	利息收入	8,976	2,156
Government grants	政府補助	237	217
Others	其他	339	11
		49,786	28,593

5. 其他收入及收益

其他收入及收益的分析如下：

6. FINANCE COSTS

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Interest on lease liabilities	租賃負債的利息	275	192

6. 財務成本

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

7. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging:

7. 除稅前虧損

本集團除稅前虧損乃於扣除以下各項後得出：

		For the six months ended	
		30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Cost of inventories sold	已售存貨成本	18,801	4,456
Depreciation of property, plant and equipment	物業、廠房及設備折舊	8,412	8,032
Depreciation of right-of-use assets	使用權資產折舊	4,192	2,865
Amortisation of other intangible assets	其他無形資產攤銷	941	—
Impairment of financial assets, net:	金融資產減值淨額：		
Impairment of trade receivables, net	應收賬款減值淨額	2,840	707
Impairment of other receivables, net	其他應收款項減值淨額	98	11
(Reversal of impairment)/impairment of guarantee contract	擔保合約(減值撥回)/減值	(2,990)	2,990
Employee benefit expenses:	僱員福利開支：		
Salaries, wages and other benefits	薪金、工資及其他福利	80,774	79,482
Defined contribution retirement plans	設定提存退休計劃	6,132	5,959
Share-based payments	股份支付	11,147	17,248

8. INCOME TAX EXPENSE

The Group is subject to income tax on an entity basis on profits arising in or derived from the jurisdictions in which members of the Group are domiciled and operate.

Under the relevant PRC income tax law, entities qualified as high-technology enterprises are entitled to a preferential income tax rate of 15%. The Company and three subsidiaries were recognised as high-technology enterprises and are subject to income tax at 15%.

8. 所得稅開支

本集團須就本集團成員公司在所在及經營的司法管轄區所產生的溢利按實體基準繳納所得稅。

根據相關中國所得稅法，具有高新技術企業資格的實體有權享受15%的所得稅優惠稅率。本公司及三間附屬公司獲認定為高新技術企業，並按15%的稅率繳納所得稅。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

8. INCOME TAX EXPENSE (continued)

Under the relevant PRC income tax law, the PRC subsidiaries of the Group are subject to income tax at a rate of 25% on their respective taxable income except for the Company and the three subsidiaries.

8. 所得稅開支(續)

根據相關中國所得稅法，除本公司及三家附屬公司外，本集團的中國附屬公司均須按其相關應課稅收入的25%稅率繳納所得稅。

For the six months ended 30 June

截至6月30日止六個月

		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Current — Mainland	當期稅項 — 內地	(488)	—
Total tax expense for the period	期內稅項開支總額	<u>(488)</u>	<u>—</u>

9. DIVIDENDS

No dividends were declared or paid by the Company during the six months ended 30 June 2023 (six months ended 30 June 2022: Nil).

9. 股息

截至2023年6月30日止六個月，本公司並無宣派或派付股息(截至2022年6月30日止六個月：無)。

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The calculation of the basic loss per share amount is based on the loss for the period attributable to ordinary equity holders of the parent, and the weighted average number of ordinary shares of 103,568,000 (2022: 101,248,000) in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the periods ended 30 June 2023 and 2022.

10. 母公司普通權益持有人應佔每股虧損

每股基本虧損金額乃根據母公司普通權益持有人應佔期內虧損，以及期內已發行普通股加權平均數103,568,000股(2022年：101,248,000股)計算。

截至2023年及2022年6月30日止期間呈列的每股基本虧損金額並未作出調整。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

10. LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT (continued)

The calculations of basic and diluted loss per share are based on:

10. 母公司普通權益持有人應佔每股虧損(續)

每股基本虧損及攤薄虧損的計算乃基於：

		For the six months ended	
		30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
		RMB'000	RMB'000
		人民幣千元	人民幣千元
Loss	虧損		
Loss attributable to ordinary equity holders of the parent, used in the basic and diluted loss per share calculation	母公司普通權益持有人應佔虧損，用以計算每股基本及攤薄虧損	<u>36,970</u>	<u>99,684</u>
		Number of shares	
		股份數目	
		For the six months ended	
		30 June	
		截至6月30日止六個月	
		2023	2022
		2023年	2022年
Shares	股份		
Weighted average number of ordinary shares in issue during the period used in the basic and diluted loss per share calculation	期內已發行普通股加權平均數用以計算每股基本及攤薄虧損	<u>103,568,000</u>	<u>101,248,000</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

11. PROPERTY, PLANT AND EQUIPMENT

During the six months ended 30 June 2023, the Group acquired assets at a cost of RMB2,161,000 (30 June 2022: RMB4,173,000), excluding property, plant and equipment acquired through a business combination.

Assets with a net book value of RMB1,136,000 were disposed of by the Group during the six months ended 30 June 2023 (30 June 2022: RMB1,248,000), resulting in a net loss on disposal of RMB973,000 (30 June 2022: Nil).

During the six months ended 30 June 2023, an impairment loss of nil (30 June 2022: Nil) was recognised for certain property, plant and equipment.

12. TRADE RECEIVABLES

Trade receivables
Impairment

應收賬款
減值

11. 物業、廠房及設備

截至2023年6月30日止六個月，本集團以成本人民幣2,161,000元（2022年6月30日：人民幣4,173,000元）收購資產，不包括通過業務合併取得的物業、廠房及設備。

截至2023年6月30日止六個月，本集團處置賬面淨值為人民幣1,136,000元的資產（2022年6月30日：人民幣1,248,000元），所產生處置淨虧損為人民幣973,000元（2022年6月30日：零）。

截至2023年6月30日止六個月，就若干物業、廠房及設備確認的減值虧損為零（2022年6月30日：零）。

12. 應收賬款

30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
90,139	70,407
(9,370)	(6,530)
<u>80,769</u>	<u>63,877</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

12. TRADE RECEIVABLES (continued)

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	52,831	55,842
6 to 12 months	6至12個月	27,557	6,875
Over 12 months	12個月以上	381	1,160
		<u>80,769</u>	<u>63,877</u>

13. PREPAYMENTS, OTHER RECEIVABLES AND OTHER ASSETS

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Deposits	按金	1,642	877
Prepayments to suppliers	向供應商支付的 預付款項	15,831	10,669
VAT recoverable	可收回增值稅	6,102	5,050
Others	其他	4,174	2,966
		<u>27,749</u>	<u>19,562</u>
Less: loss allowance	減：虧損撥備	(274)	(176)
		<u>27,475</u>	<u>19,386</u>

12. 應收賬款(續)

於報告期末，按發票日期為基準及經扣除虧損撥備的應收賬款的賬齡分析如下：

13. 預付款項、其他應收款項及其他資產

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

14. OTHER FINANCIAL ASSETS

14. 其他金融資產

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Financial assets measured at amortised cost	按攤銷成本計量的金融資產	36,129	35,593
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	343,332	126,186
Equity investments designated at fair value through other comprehensive income	指定為按公允價值計量且其變動計入其他綜合收益的權益投資	2,456	3,274
		<u>381,917</u>	<u>165,053</u>
Classified as:	歸類為：		
Current assets	流動資產	276,497	144,734
Non-current assets	非流動資產	105,420	20,319
		<u>381,917</u>	<u>165,053</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

15. CASH AND CASH EQUIVALENTS

15. 現金及現金等價物

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Cash and bank balances	現金及銀行結餘	969,508	1,418,250
Less: Time deposits over three months (note 1)	減：超過三個月的 定期存款 (附註1)	(93,148)	—
Restricted bank deposits (note 2)	受限制銀行存款 (附註2)	—	(150,000)
Cash and cash equivalents	現金及現金等價物	<u>876,360</u>	<u>1,268,250</u>

Note 1: The original maturity of the time deposits was more than three months but less than one year.

附註1：定期存款的原到期日為超過三個月但少於一年。

Note 2: Restricted bank deposits of RMB150,000,000 have been pledged to secure third party notes, which have been recovered during the period.

附註2：受限制銀行存款人民幣150,000,000元已抵押用於擔保第三方票據，並已於本期間收回。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

16. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Within 6 months	6個月內	17,129	6,625
6 months to 1 year	6個月至1年	5,739	—
		<u>22,868</u>	<u>6,625</u>

16. 應付賬款

於報告期末，應付賬款按發票日期的賬齡分析如下：

17. OTHER PAYABLES AND ACCRUALS

		30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
Accrued payroll	應計薪金	9,410	10,891
Other taxes payable	其他應繳稅款	13,665	7,036
Accrued expenses	應計開支	5,333	9,654
Listing expenses payable	應付上市開支	—	1,381
Other payables	其他應付款項	3,002	6,442
		<u>31,410</u>	<u>35,404</u>

17. 其他應付款項及應計費用

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

18. SHARE CAPITAL

Issued and fully paid:	已發行及繳足：
103,568,000 (31 December 2022:	103,568,000股
103,568,000) ordinary shares of	(於2022年
RMB1 each	12月31日：
	103,568,000股)
	每股面值人民幣
	1元的普通股

18. 股本

30 June 2023 於2023年 6月30日 (Unaudited) (未經審核) RMB'000 人民幣千元	31 December 2022 於2022年 12月31日 (Audited) (經審核) RMB'000 人民幣千元
103,568	103,568

19. EQUITY-SETTLED SHARE-BASED TRANSACTION

During the year ended 31 December 2021, 2,319,588 restricted share units were granted to a director and certain employees of the Group at a price of RMB13.87 per share unit. The restricted stock units (“RSUs”) granted on 1 November 2021 will be vested in tranches of 25% each at the end of the fourth month, the sixteenth month, the twenty-eighth month and fortieth month, respectively, from the date of grant upon the achievement of service period condition. The RSUs granted on 31 December 2021 are subject to a vesting scale in tranches of 25% each per annum from the date of grant upon the achievement of service period condition.

On 30 March 2023, the Group granted 3,107,040 restricted shares at the price of RMB0.00 per share unit to Mr. Zhang and the RSUs will be vested in tranches of 25% each at the end of the ninth month, the twenty-first month, the thirty-third month and forty-fifth month, respectively.

19. 以權益結算的股份支付交易

截至2021年12月31日止年度，本集團以每股份單位人民幣13.87元的價格向一位董事及若干僱員授出2,319,588份受限制股份單位。於2021年11月1日授予的受限制股份單位（「受限制股份單位」）將於達成服務期限條件後分別自授出日期起的第4個月末、第16個月末、第28個月末和第40個月末按每批25%的比例歸屬。於2021年12月31日授出的受限制股份單位將於達成服務期限條件後自授出日期起，按每年每批25%的比例歸屬。

於2023年3月30日，本集團以每股份單位人民幣0.00元的價格向張先生授出3,107,040股受限制股份，且受限制股份單位將分別於第9個月末、第21個月末、第33個月末和第45個月末按每批25%的比例歸屬。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

19. EQUITY SETTLED SHARE-BASED TRANSACTION (continued)

19. 以權益結算的股份支付交易 (續)

The number and movements of RSUs are as follows:

受限制股份單位的數目及變動如下：

At 1 January 2022 (audited)	於2022年1月1日(經審核)	2,319,588
Forfeited during the year	於年內已失效	(258,671)
Vested during the year	於年內歸屬	<u>(470,229)</u>
At 31 December 2022 and 1 January 2023 (audited)	於2022年12月31日及 2023年1月1日(經審核)	<u>1,590,688</u>
Granted during the period	於期內授予	3,107,040
Forfeited during the period	於期內已失效	(247,197)
Vested during the period	於期內歸屬	<u>(135,641)</u>
At 30 June 2023 (unaudited)	於2023年6月30日(未經審核)	<u>4,314,890</u>

As at 30 June 2023, 4,314,890 shares of RSUs remained unvested. The grant date fair value of the RSUs granted on 1 November 2021 and on 31 December 2021 was determined based on the difference between the market share price at the grant date and the price of the RSUs payable by the grantee of RMB13.87 per share unit. The grant date fair value of the RSUs granted on 30 March 2023 was determined based on the market share price at the grant date of RMB13.34. The weighted average grant date fair values of these RSUs issued on 1 November 2021, 31 December 2021 and 30 March 2023 are RMB61.73, RMB31.40 and RMB13.34 per share unit, respectively.

於2023年6月30日，受限制股份單位中4,314,890股股份仍未歸屬。於2021年11月1日及2021年12月31日授予的受限制股份單位的授予日公允價值按授出日期的市場股價與承授人應付的受限制股份單位價格按每股份單位人民幣13.87元的差額釐定。於2023年3月30日授予的受限制股份單位的授予日公允價值按授出日期的市場股價人民幣13.34元釐定。於2021年11月1日、2021年12月31日及2023年3月30日發行之此等受限制股份單位的授予日加權平均公允價值分別為每股份單位人民幣61.73元、人民幣31.40元及人民幣13.34元。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

20. BUSINESS COMBINATION

On 29 May 2023, the Group acquired a 70% interest in Beijing Zhitong Technology Co., Ltd and its subsidiaries (“**Beijing Zhitong Group**”) from the industry fund at a total consideration of RMB182 million. The Industry Fund is a PRC-incorporated fund engaged in the investment in healthcare industry. The general partner of the Industry Fund is Shanghai Ruishi Wealth Investment Management Co., Ltd. (上海瑞世財富投資管理有限公司) (the “**Fund Manager**”), which is directly controlled as to 33.33% by Yang Xiaorong (楊曉蓉) as its ultimate beneficially owner. The Industry Fund has four limited partners, except for Beijing Zhongguan Zhihe Technology Co., Ltd. (北京中觀智和科技有限公司) holding 62.7% of the limited partnership interest and the Company holding 18.1% of the limited partnership interest in the Industry Fund, none of the other limited partners holds more than 30% partnership interest in the Industry Fund.

The above-mentioned Acquisition is expected to bring significant synergistic effects to the current business of the Group, as the Company is able to enhance Beijing Zhitong Group’s existing products by introducing the Company’s AI detection and diagnosis technologies and thereby extend the Group’s current business from AI detection and diagnosis to AI-based medical treatment and further strengthen the Group’s current product portfolio.

20. 業務合併

於2023年5月29日，本集團自產業基金收購北京智瞳科技有限公司及其附屬公司(「北京智瞳集團」)70%的股權，總代價為人民幣182百萬元。產業基金為一家於中國註冊成立的基金，從事醫療保健行業投資。產業基金的普通合夥人為上海瑞世財富投資管理有限公司(「基金管理人」)，由其最終實益擁有人楊曉蓉直接控制33.33%的權益。產業基金擁有四名有限合夥人，除北京中觀智和科技有限公司及本公司分別於產業基金持有62.7%及18.1%有限合夥權益外，其他有限合夥人概無於產業基金持有超過30%的合夥權益。

上述收購事項預期將為本集團現有業務帶來顯著的協同效應，因為本公司能夠通過引入本公司的人工智能檢測及診斷技術以加強北京智瞳集團的現有產品，從而將本集團現有業務從人工智能檢測及診斷擴展至基於人工智能的醫療，並進一步加強本集團現有產品組合。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

20. BUSINESS COMBINATION (continued)

The fair values of the identifiable assets and liabilities of Beijing Zhitong Group as at the date of acquisition were as follows:

20. 業務合併 (續)

北京智瞳集團於收購日期可識別資產及負債的公允價值如下：

		Fair value recognised on acquisition 於收購時確認的 公允價值 RMB'000 人民幣千元 (Unaudited) (未經審核)
Other intangible assets	其他無形資產	92,000
Inventories	存貨	10,960
Trade receivables	應收賬款	2,968
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	638
Cash and cash equivalents	現金及現金等價物	5,190
Trade payables	應付賬款	(12,298)
Other payables and accruals	其他應付款項及應計費用	(4,423)
Tax payable	應付稅項	(3,191)
Deferred tax liabilities	遞延稅項負債	(13,800)
Total identifiable net assets at fair value	以公允價值計量的可識別資產淨值總額	78,044
Non-controlling interests	非控股權益	(23,412)
Goodwill on acquisition	收購的商譽	127,368
Satisfied by cash	以現金償付	182,000

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

20. BUSINESS COMBINATION (continued)

20. 業務合併(續)

An analysis of the cash flows in respect of the acquisition of subsidiaries is as follows:

收購附屬公司的現金流量分析如下：

		The cash flows in respect of the acquisition of subsidiaries 收購附屬公司的 現金流量 RMB'000 人民幣千元 (Unaudited) (未經審核)
Cash consideration	現金代價	(182,000)
Cash and bank balances acquired	收購的現金及銀行結餘	<u>5,190</u>
Net outflow of cash and cash equivalents included in cash flows from investing activities	計入投資活動所得現金流量的現金及現金等價物流出淨額	<u><u>(176,810)</u></u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

20. BUSINESS COMBINATION (continued)

20. 業務合併(續)

Reconciliation of the carrying amount of the Group's goodwill at the beginning and end of the reporting period is presented below:

本集團商譽於報告期初及期末的賬面值對賬呈列如下：

		RMB'000 人民幣千元 (Unaudited) (未經審核)
Gross carrying amount	總賬面值	
At 1 January 2023	於2023年1月1日	970
Acquisition of subsidiaries	收購附屬公司	127,368
		<u>128,338</u>
At 30 June 2023	於2023年6月30日	<u>128,338</u>
Accumulated impairment losses	累計減值虧損	
At 1 January 2023 and at 30 June 2023	於2023年1月1日及 2023年6月30日	—
		<u>—</u>
Net book value	賬面淨值	
At 1 January 2023	於2023年1月1日	970
		<u>970</u>
At 30 June 2023	於2023年6月30日	<u>128,338</u>

Since the acquisition, Beijing Zhitong Technology Co., Ltd contributed RMB10,715,000 (unaudited) to the Group's revenue and RMB1,125,000 (unaudited) to the consolidated profit for the six months ended 30 June 2023.

自收購起，截至2023年6月30日止六個月，北京智瞳科技有限公司為本集團貢獻收入人民幣10,715,000元(未經審核)及貢獻綜合溢利人民幣1,125,000元(未經審核)。

Had the combination taken place at the beginning of the period, the revenue of the Group and the loss of the Group for the period would have been RMB100,901,000 (unaudited) and RMB55,116,000 (unaudited), respectively.

倘合併於期初進行，本集團的期內收入及虧損將分別為人民幣100,901,000元(未經審核)及人民幣55,116,000元(未經審核)。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

21. RELATED PARTY TRANSACTIONS

(a) Name and relationship

The directors of the Group are of the opinion that the following companies are related parties that had transactions or balances with the Group during the reporting period.

Name of related parties

關聯方名稱

Ping An Health Internet Co., Ltd
平安健康互聯網股份有限公司

Relationship with the Group

與本集團的關係

A fellow subsidiary of non-controlling interests
非控股權益的同系附屬公司

(b) Transactions with related parties

In addition to the transactions detailed elsewhere in this interim condensed consolidated financial information, the Group had the following transactions with related parties for the six months ended 30 June 2023 and 2022:

21. 關聯方交易

(a) 名稱及關係

本集團董事認為下列公司乃為於報告期內與本集團存在交易或結餘的關聯方。

(b) 與關聯方的交易

除於本中期簡明綜合財務資料其他部分詳述的交易外，截至2023年及2022年6月30日止六個月，本集團與關聯方進行的交易如下：

For the six months ended

30 June

截至6月30日止六個月

	2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Provision of AI-based software solutions: Ping An Health Internet Co., Ltd	4	669

提供人工智能軟件
解決方案：

平安健康互聯網股份
有限公司

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

21. RELATED PARTY TRANSACTIONS

(continued)

(c) Balances with related parties

		30 June 2023 於2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 於2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Trade receivables:	應收賬款：		
Ping An Health Internet Co., Ltd	平安健康互聯網股份 有限公司	105	113
Prepayments, other receivables and other assets:	預付款項、其他應收 款項及其他資產：		
Ping An Health Internet Co., Ltd	平安健康互聯網股份 有限公司	—	30

(d) Compensation of key management personnel of the Group:

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Short term employee benefits	短期僱員福利	3,298	3,114
Post-employment benefits	離職後福利	168	165
Equity-settled share based payments	以權益結算的股份 支付	7,110	1,190
Total compensation paid to key management personnel	已付關鍵管理人員之 酬金總額	10,576	4,469

21. 關聯方交易 (續)

(c) 與關聯方的結餘

		30 June 2023 於2023年 6月30日 RMB'000 人民幣千元 (Unaudited) (未經審核)	31 December 2022 於2022年 12月31日 RMB'000 人民幣千元 (Audited) (經審核)
Trade receivables:	應收賬款：		
Ping An Health Internet Co., Ltd	平安健康互聯網股份 有限公司	105	113
Prepayments, other receivables and other assets:	預付款項、其他應收 款項及其他資產：		
Ping An Health Internet Co., Ltd	平安健康互聯網股份 有限公司	—	30

(d) 本集團關鍵管理人員酬金：

		For the six months ended 30 June 截至6月30日止六個月	
		2023 2023年 (Unaudited) (未經審核) RMB'000 人民幣千元	2022 2022年 (Unaudited) (未經審核) RMB'000 人民幣千元
Short term employee benefits	短期僱員福利	3,298	3,114
Post-employment benefits	離職後福利	168	165
Equity-settled share based payments	以權益結算的股份 支付	7,110	1,190
Total compensation paid to key management personnel	已付關鍵管理人員之 酬金總額	10,576	4,469

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The Group's finance department headed by the finance manager is responsible for determining the policies and procedures for the fair value measurement of financial instruments. The finance manager reports directly to the chief financial officer and the audit committee. At each reporting date, the finance department analyses the movements in the values of financial instruments and determines the major inputs applied in the valuation. The valuation is reviewed and approved by the chief financial officer. The valuation process and results are discussed with the audit committee twice a year for interim and annual financial reporting.

The fair values of the financial assets are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values of those financial assets:

22. 金融工具公允價值和公允價值等級

本集團以財務經理為首的財務部門負責釐定金融工具公允價值計量的政策及程序。財務經理直接向首席財務官及審核委員會報告。於各報告日期，財務部門分析金融工具的價值變動並釐定估值所適用的主要輸入數據。估值由首席財務官審核並批准。估值過程及結果與審核委員會每年討論兩次以進行中期及年度財務申報。

金融資產的公允價值按自願方之間的當前交易（強迫或清算銷售除外）中可交換工具的金額列賬。估計該等金融資產的公允價值時已採用以下方法及假設：

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

The fair values of unlisted equity investments designated at fair value through other comprehensive income have been estimated using a market-based valuation technique based on assumptions. The valuation requires the directors to determine comparable public companies (peers) based on industry, size, leverage and strategy, and to calculate an appropriate price multiple, for each comparable company identified. The multiple is calculated by dividing the market capitalization of the comparable company by sales measure. The trading multiple is then discounted for considerations between the comparable companies based on company-specific facts and circumstances. The discounted multiple is applied to the corresponding earnings measure of the unlisted equity investments to measure the fair value. The directors believe that the estimated fair values resulting from the valuation technique, which are recorded in the interim condensed consolidated statement of financial position, and the related changes in fair values, which are recorded in other comprehensive income, are reasonable, and that they were the most appropriate values at the end of the reporting period.

The Group invests in unlisted investments and financial products, which represent wealth management products issued by banks in Mainland China and Hong Kong. The Group has estimated the fair value of these financial products and unlisted investments by using a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks.

For the fair value of the unlisted equity investments at fair value through other comprehensive income, management has estimated the potential effect of using reasonably possible alternatives as inputs to the valuation model.

22. 金融工具公允價值和公允價值等級 (續)

指定以公允價值計量且其變動計入其他綜合收益的非上市權益投資的公允價值已使用市場估值法，根據假設進行估計。估值須董事根據行業、規模、槓桿比率及策略釐定可資比較公眾公司(同業)，並就所識別的各可資比較公司計算合適價格倍數。倍數乃將可資比較公司之市值除以銷量計量而計算。隨後，交易倍數將在考慮可資比較公司的差異後根據公司特定事實及情況作出折讓。經折讓倍數將應用於非上市權益投資的相應盈利計量以計量公允價值。董事相信，由估值方法產生的估計公允價值(已於中期簡明綜合財務狀況表入賬)及相關公允價值變動(已於其他綜合收益入賬)乃屬合理，且其為於報告期末的最適當價值。

本集團對非上市投資及金融產品(即於中國內地及香港之銀行發行的理財產品)進行投資。本集團已根據具有類似條款及風險的工具的市場利率採用貼現現金流估值模式估計該等金融產品及非上市投資的公允價值。

就以公允價值計量且其變動計入其他綜合收益的非上市權益投資的公允價值而言，管理層已對在估值模型中運用合理可能的替代輸入數據的潛在影響作出估計。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2023

22. 金融工具公允價值和公允價值等級 (續)

公允價值層級

下表闡明本集團金融工具公允價值計量等級：

按公允價值計量的資產：

於2023年6月30日

		Fair value measurement using 公允價值計量採用以下基準			
		Quoted prices in active markets	Significant observable inputs	Significant unobservable inputs	Total
		活躍市場報價 (Level 1) (第一層級)	重大可觀察 輸入數據 (Level 2) (第二層級)	重大影響的 不可觀察 輸入數據 (Level 3) (第三層級)	總計
		RMB'000 人民幣千元 (Unaudited) (未經審核)	RMB'000 人民幣千元 (Unaudited) (未經審核)	RMB'000 人民幣千元 (Unaudited) (未經審核)	RMB'000 人民幣千元 (Unaudited) (未經審核)
Equity investments designated at fair value through other comprehensive income	指定為以公允價值計量 且其變動計入其他 綜合收益的權益 投資	—	2,456	—	2,456
Financial assets at fair value through profit or loss	以公允價值計量且 其變動計入當期 損益的金融資產	—	—	343,332	343,332
		—	2,456	343,332	345,788

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy (continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments: (continued)

Assets measured at fair value: (continued)

As at 31 December 2022

22. 金融工具公允價值和公允價值等級 (續)

公允價值層級 (續)

下表闡明本集團金融工具公允價值計量等級：(續)

以公允價值計量的資產：(續)

於2022年12月31日

		Fair value measurement using 公允價值計量採用以下基準			
		Quoted prices in active markets (Level 1) (第一層級) RMB'000 人民幣千元 (Audited) (經審核)	Significant observable inputs (Level 2) (第二層級) RMB'000 人民幣千元 (Audited) (經審核)	Significant unobservable inputs (Level 3) (第三層級) RMB'000 人民幣千元 (Audited) (經審核)	Total 總計 RMB'000 人民幣千元 (Audited) (經審核)
Equity investments designated at fair value through other comprehensive income	指定為以公允價值計量且其變動計入其他綜合收益的權益投資	—	3,274	—	3,274
Financial assets at fair value through profit or loss	以公允價值計量且其變動計入當期損益的金融資產	—	—	126,186	126,186
		—	3,274	126,186	129,460

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (continued)

Fair value hierarchy (continued)

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments: (continued)

Assets measured at fair value: (continued)

The movements in fair value measurements within Level 3 during the period are as follows:

22. 金融工具公允價值和公允價值等級 (續)

公允價值層級 (續)

下表闡明本集團金融工具公允價值計量等級：(續)

以公允價值計量的資產：(續)

期內，第三層級中的公允價值計量變動如下：

		2023 2023年 RMB'000 人民幣千元 (Unaudited) (未經審核)	2022 2022年 RMB'000 人民幣千元 (Unaudited) (未經審核)
Financial assets at fair value through profit or loss:	以公允價值計量且其變動計入當期損益的金融資產：		
At 1 January	於1月1日	126,186	—
Total gains recognised in other income in the interim condensed consolidated statement of profit or loss	於中期簡明綜合損益表的其他收入確認的收益總額	9,841	7,549
Purchases	購買	224,350	1,161,876
Redemption	贖回	(17,045)	(1,068,537)
At 30 June	於6月30日	<u>343,332</u>	<u>100,888</u>

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION 中期簡明綜合財務資料附註

30 June 2023 於2023年6月30日

22. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS *(continued)*

Fair value hierarchy *(continued)*

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments: *(continued)*

Liabilities measured at fair value:

The Group did not have any financial liabilities measured at fair value as at 30 June 2023 and 31 December 2022.

During the period, there were no transfers of fair value measurements between Level 1 and Level 2 and no transfers into or out of Level 3 for financial assets (six months ended 30 June 2022: Nil).

23. EVENTS AFTER THE REPORTING PERIOD

There were no significant events of the Group after the reporting period.

22. 金融工具公允價值和公允價值等級 *(續)*

公允價值層級 *(續)*

下表闡明本集團金融工具公允價值計量等級：*(續)*

按公允價值計量的負債：

於2023年6月30日及2022年12月31日，本集團並無任何按公允價值計量的金融負債。

於期內，金融資產在第一層級與第二層級之間並無公允價值層級轉撥，亦無轉至或轉出第三層級（截至2022年6月30日止六個月：無）。

23. 報告期後事項

本集團於報告期後概無重大事項。

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

<p>“2022 Equity Incentive Scheme”</p> <p>「2022年股權激勵計劃」</p>	<p>the equity incentive scheme adopted by the Board in accordance with the rules thereof on January 13, 2023 and approved by the Shareholders on the extraordinary general meeting of the Company held on March 30, 2023, the details of which are set out in the circular of the Company dated March 10, 2023</p> <p>指 董事會於2023年1月13日根據其規則採納之股權激勵計劃，並經股東於本公司於2023年3月30日舉行的股東特別大會上批准，其詳情載於本公司日期為2023年3月10日之通函</p>
<p>“AI”</p> <p>「人工智能」</p>	<p>artificial intelligence</p> <p>指 人工智能</p>
<p>“Airdoc”, “Group”, “we” or “us”</p> <p>「鷹瞳」、「本集團」或「我們」</p>	<p>our Company and all of our subsidiaries or, where the context so requires, in respect of the period before our Company became the holding company of its present subsidiaries, the businesses operated by such subsidiaries or their predecessors (as the case may be)</p> <p>指 本公司及我們的所有附屬公司，或倘文義指明，就本公司成為其目前附屬公司的控股公司之前的期間而言，指由該等附屬公司或他們的前身（視情況而定）所經營的業務</p>
<p>“Airdoc Universe”</p> <p>「鬱金香宇宙」</p>	<p>Beijing Airdoc Universe Technology Center L.P. (北京鬱金香宇宙科技中心(有限合夥)), a limited partnership established in the PRC on February 22, 2016 and an employee incentive platform of our Group</p> <p>指 北京鬱金香宇宙科技中心(有限合夥)，一家於2016年2月22日在中國成立的有限合夥公司，為本集團僱員激勵平台</p>
<p>“associate(s)”</p> <p>「聯繫人」</p>	<p>has the meaning ascribed to it under the Listing Rules</p> <p>指 具有上市規則所賦予的涵義</p>
<p>“Audit Committee”</p> <p>「審核委員會」</p>	<p>the audit committee of the Board</p> <p>指 董事會審核委員會</p>
<p>“Board” or “Board of Directors”</p> <p>「董事會」</p>	<p>the board of directors of our Company</p> <p>指 本公司董事會</p>

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

“Class III medical device”	medical devices with relatively high risks, which shall be strictly controlled and administered through special measures to ensure their safety and effectiveness under the Regulation on the Supervision and Administration of Medical Devices (《醫療器械監督管理條例》)
「第三類醫療器械」	指 根據《醫療器械監督管理條例》，具有相對較高風險，需要採取特別措施嚴格控制管理以保證其安全有效的醫療器械
“Companies Ordinance”	the Companies Ordinance, Chapter 622 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
「公司條例」	指 香港法例第622章公司條例(經不時修訂、補充或以其他方式修改)
“Company”, “our Company” or “the Company”	Beijing Airdoc Technology Co., Ltd. (北京鷹瞳科技發展股份有限公司), a joint stock company incorporated in the PRC with limited liability on September 9, 2015
「本公司」	指 北京鷹瞳科技發展股份有限公司，一家於2015年9月9日在中國註冊成立的股份有限公司
“Concert Party Agreement”	the agreement entered into between Mr. Zhang, Mr. Chen and Mr. Gao on October 14, 2016, pursuant to which Mr. Chen and Mr. Gao have undertaken to, among other things, vote unanimously with Mr. Zhang for any resolutions proposed at any Board and Shareholders’ meetings of our Company
「一致行動人士協議」	指 根據張先生、陳先生及高先生於2016年10月14日達成的協議，陳先生及高先生已承諾(其中包括)就於本公司董事會及股東大會上提出的任何決議案與張先生一致投票
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for the purpose of this interim report, our Core Product refers to our Airdoc-AIFUNDUS
「核心產品」	指 具有上市規則第18A章賦予的涵義；就本中期報告而言，我們的核心產品指Airdoc-AIFUNDUS
“Corporate Governance Code”	the Corporate Governance Code as set out in Appendix 14 to the Listing Rules
「企業管治守則」	指 上市規則附錄十四所載企業管治守則
“CSDC”	China Securities Depository and Clearing Co., Ltd. (中國證券登記結算有限責任公司)
「中國結算」	指 中國證券登記結算有限責任公司

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會), a regulatory body responsible for the supervision and regulation of the PRC national securities markets
「中國證監會」	指 中國證券監督管理委員會，為負責監督及規管中國國家證券市場的監管機構
“Director(s)”	the director(s) of our Company, including all executive, non-executive and independent non-executive directors
「董事」	指 本公司董事，包括所有執行董事、非執行董事及獨立非執行董事
“Global Offering”	the Hong Kong Public Offering and the International Offering
「全球發售」	指 香港公开发售及國際發售
“H Share(s)”	overseas listed foreign share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are to be listed on the Stock Exchange and traded in Hong Kong dollars
「H股」	指 指本公司股本中每股面值人民幣1.00元的境外上市外資股，將於聯交所上市並以港元交易
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
「港元」	指 港元，香港法定貨幣
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
「香港」	指 中國香港特別行政區
“IASB”	International Accounting Standards Board
「國際會計準則理事會」	指 國際會計準則理事會
“ICVD”	ischemic cardiovascular disease, including myocardial infarction and cerebral infarction
「ICVD」	指 缺血性心血管疾病，包括心肌梗塞及腦梗塞
“IFRS”	International Financial Reporting Standards
「國際財務報告準則」	指 國際財務報告準則
“Listing” or “IPO”	the listing of our Shares on the Stock Exchange
「上市」或「首次公开发售」	指 我們的股份於聯交所上市
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange, as amended or supplemented from time to time
「上市規則」	指 聯交所證券上市規則（經不時修訂或補充）

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuers set out in Appendix 10 of the Listing Rules
「標準守則」	指 上市規則附錄十所載的上市發行人董事進行證券交易的標準守則
“Mr. Chen”	Mr. Chen Mingqiang (陳明強), one of our co-founders and a member of the single largest group of Shareholders
「陳先生」	指 陳明強先生，乃我們的聯合創始人之一及單一最大股東集團的成員
“Mr. Gao”	Mr. Gao Fei (高斐), one of our co-founders, an executive Director and a member of the single largest group of Shareholders
「高先生」	指 高斐先生，乃我們的聯合創始人之一、執行董事及單一最大股東集團成員
“Mr. Zhang”	Mr. Zhang Dalei (張大磊), our founder, the chairman of the Board, an executive Director and a member of the single largest group of Shareholders
「張先生」	指 張大磊先生，乃我們的創始人、董事會主席、執行董事及單一最大股東集團成員
“NMPA”	the National Medical Products Administration of China (國家藥品監督管理局)
「國家藥監局」	指 國家藥品監督管理局
“Nomination Committee”	the nomination committee of the Board
「提名委員會」	指 董事會提名委員會
“OEM”	acronym for original equipment manufacturer, a business that manufactures goods or equipment for branding and release by others
「原設備製造商」	指 原設備製造商(縮寫為OEM)，製造貨品或設備供他人創建品牌或發佈產品的企業
“Ping An Healthtech”	Ping An Healthtech Co., Ltd. (平安醫療科技有限公司), a company established in the PRC with limited liability on September 28, 2017
「平安醫療科技」	指 平安醫療科技有限公司，一家於2017年9月28日在中國成立的有限公司

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

“pricing guidance” 「定價指引」	a guidance issued by governmental authorities, which is a prerequisite for the public hospitals to set specific charging items for medical service and charge patients accordingly 指 政府機關發佈的指引，為公共醫院為醫療服務設置特定收費項目，並據此作為向患者收費的先決條件
“Prospectus” 「招股章程」	the prospectus issued by the Company dated October 26, 2021 指 本公司於2021年10月26日發佈的招股章程
“R&D” 「研發」	Research and Development 指 研究及開發
“Remuneration and Appraisal Committee” 「薪酬與考核委員會」	the remuneration and appraisal committee of the Board 指 董事會薪酬與考核委員會
“Reporting Period” 「報告期」	the six months ended June 30, 2023 指 截至2023年6月30日止六個月
“RMB” 「人民幣」	Renminbi Yuan, the lawful currency of China 指 中國的法定貨幣人民幣
“SaMD(s)” 「SaMD」	Software as a Medical Device, a class of medical software designed to carry out one or more medical functions without the need for actual hardware 指 作為醫療器械的軟件，是一類無需實際硬件即可用於執行一種或多種醫療功能的醫療軟件
“SFO” 「證券及期貨條例」	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time 指 香港法例第571章所載證券及期貨條例（經不時修訂或補充）
“Share(s)” 「股份」	shares in the share capital of our Company, with a nominal value of RMB1.00 each, comprising Unlisted Shares and H Shares 指 本公司股本中每股面值人民幣1.00元的股份，包括未上市股份及H股
“Shareholder(s)” 「股東」	holder(s) of the Share(s) 指 股份持有人

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

“Shiji Sisu” 「世紀思速」	Beijing Shi Ji Si Su Technology Co., Ltd. (北京世紀思速科技有限公司), a company established in the PRC with limited liability on May 31, 2009 指 北京世紀思速科技有限公司，一家於2009年5月31日在中國成立的有限責任公司
“Sogou Information” 「搜狗信息」	Beijing Sogou Information Service Co., Ltd (北京搜狗信息服務有限公司), a company established in the PRC with limited liability on December 28, 2005 指 北京搜狗信息服務有限公司，一家於2005年12月28日在中國成立的有限責任公司
“Stock Exchange” 「聯交所」	The Stock Exchange of Hong Kong Limited 指 香港聯合交易所有限公司
“Strategy Committee” 「戰略委員會」	the strategy committee of the Board 指 董事會戰略委員會
“subsidiary(ies)” 「附屬公司」	has the meaning ascribed to it in section 15 of the Companies Ordinance 指 具有公司條例第15條所賦予的涵義
“Substantial Shareholder(s)” 「主要股東」	has the meaning ascribed to it under the Listing Rules 指 具有上市規則所賦予的涵義
“Supervisor(s)” 「監事」	supervisor(s) of our Company 指 本公司監事
“Suqian Airdoc” 「宿遷鷹瞳」	Suqian Airdoc Technology Center (Limited Partnership) (宿遷鷹瞳科技中心(有限合夥)), a limited partnership established in the PRC on October 13, 2020 and an employee incentive platform of our Group 指 宿遷鷹瞳科技中心(有限合夥)，一家於2020年10月13日在中國成立的有限合夥公司，且為本集團僱員激勵平台
“Suqian Zhongyou” 「宿遷眾佑」	Suqian Zhongyou Technology Center (Limited Partnership) (宿遷眾佑科技中心(有限合夥)), a limited partnership established in the PRC on November 10, 2020 and an employee incentive platform of our Group 指 宿遷眾佑科技中心(有限合夥)，一家於2020年11月10日在中國成立的有限合夥公司，且為本集團僱員激勵平台

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

釋義及技術性詞彙表

the “PRC”	the People’s Republic of China but for the purpose of this interim report and for geographical reference only and except where the context requires, references in this interim report to “China” and the “PRC” do not include Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
「中國」	指 中華人民共和國，就本中期報告及僅就地域參考而言，除文義另有所指外，本中期報告提及的「中國」不包括中國香港、澳門特別行政區及台灣
“United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
「美國」	指 美利堅合眾國，其領土、屬地及受其司法管轄的所有地區
“Unlisted Share(s)”	domestic share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is(are) subscribed for and paid up in RMB by domestic investors and currently not listed on any stock exchange
「未上市股份」	指 本公司股本中每股面值人民幣1.00元的內資股，由境內投資者以人民幣認購並繳足，目前並未於任何證券交易所上市
“US\$”	United States dollars, the lawful currency of the United States
「美元」	指 美國的法定貨幣美元
“Yadong Beichen”	Yadong Beichen Venture Investment Co., Ltd. (亞東北辰創業投資有限公司), previously known as Yadong Beichen Investment Management Co., Ltd. (亞東北辰投資管理有限公司), a company established in the PRC with limited liability on August 2, 2013
「亞東北辰」	指 亞東北辰創業投資有限公司(前稱亞東北辰投資管理有限公司)，一家於2013年8月2日在中國成立的有限責任公司
For the purpose of this interim report, references to “provinces” of China include provinces, municipalities under direct administration of the central government and provincial-level, autonomous regions.	就本中期報告而言，提及中國的「省」包括省、中央政府直接管理的直轄市及省級自治區。

